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 ABSTRACT 
Axons from the central nervous system (CNS) do not regenerate, causing a 
major problem for recovery after CNS injury. One possible reason why axon 
growth is inhibited is intracellular suppression of growth signals. In this work, we 
examined the role of RTP801 during axon regeneration in vitro and in vivo. 
RTP801 is an upstream inhibitor of mTOR signalling, which is central to cell 
growth. We report here that retinal ganglion cells (RGC) in vitro and in vivo 
responded to siRNA designed against RTP801 (siRTP801). Due to a limited 
amount of time not all experiments could be repeated in triplicate however a 
trend shows that siRTP801 treatment does not enhance RGC survival or neurite 
outgrowth in vitro but increases neurite length. Treatment with siRTP801 in 
combination with ciliary neurotrophic factor (CNTF) and an anti-apoptotic 
caspase-2 inhibitor seems to be most effective in promoting long RGC neurites. 
The in vitro results support the data from the in vivo work where an increase of 
long distant axons has been documented. However, the generated data is not 
conclusive and more experiments need to be carried out. Nevertheless, these 
findings demonstrate a potential for siRTP801 as a novel strategy to enhance 
axon regeneration in RGC. 
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1. INTRODUCTION 
1.1 Axon Regeneration in the CNS after Injury 
 
Compared to the peripheral nervous system (PNS), axon regeneration of the 
central nervous system (CNS) in mature mammals is very limited. Trauma to the 
neuronal network of the CNS caused by factors, such as a stroke, brain and 
spinal cord injury or specific neurodegenerative diseases, leaves people 
suffering from irreversible neurological deficits. The reason for that is that injured 
CNS neurons exhibit an immediate axonal growth response, but this response 
ceases quickly and the original axon connections cannot be re-established (1). 
The knowledge about the pathophysiological process of CNS injury is still 
insufficient and therefore limits the discovery of novel treatments that will 
effectively induce axon growth. Hence it is necessary to gain a greater 
understanding of the underpinning mechanisms of the pathophysiology in order 
to discover more effective treatments and prevent long-term disability in patients 
suffering from CNS injury. 
1.2 The Visual System to Study CNS Regeneration 
 
Optic nerve (ON) injury is a good model in which to carry out research on CNS 
axon regeneration. Its structure is simple, with well-defined axon projections and 
it is relatively easy to access as it lies outside the cranium. The CNS axonal 
population that constitute the ON derive from the retinal ganglion cells (RGC).  
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RGC are present in the innermost layer of the retina of the eye where they 
receive information from the underlying retinal photoreceptors and relay them to 
the brain. The ON, which is made up of only RGC axons and their supporting 
cells, begins at the optic disk where RGC axons leave the orbit. It decussates 
with the ON of the other eye at the optic chiasm. From there the axons form the 
optic tracts, that will terminate in the lateral geniculate body, superior colliculus 
and the pretectal area of the brain to send information on to the visual neocortex 
and other areas.  
1.3 Strategies to Promote RGC Axon Regeneration 
 
1.3.1 Apoptotic Pathway 
RGC begin to undergo apoptosis approximately 5 days after axon injury if the 
ON is damaged intraorbitally at a gap of about 0.5mm from the eye. After two 
weeks around 90% of the RGC will have died (2).  
Apoptosis of RGC can be inhibited in several ways. One way to prevent 
apoptosis of RGC is to inhibit the intracellular signalling caspases. Caspase-2, 
for example, is evolutionary the most highly conserved caspase and functions 
both as an initiator and effector caspase (3). Levels of active caspase-2 are 
elevated after ON injury and inhibiting caspase-2 with a synthetic siRNA 
significantly increases RGC survival for 30 days post ON injury (4). This 
indicates a great neuroprotective potential of caspase-2 inhibitors. Another 
caspase inhibitor, benzyloxycarbonyl-Asp-Glu-Val-Asp-chloromethylketone, that 
inhibits caspase-3, was also demonstrated to delay RGC death (5). However, 
caspase-3 is an effector caspase and relies on activation by initiator caspases. It 
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would seem sensible to target initiator caspases rather than effector caspases 
that have less influence in preventing apoptosis. Overexpression of the anti-
apoptotic protein Bcl-2 after ON injury is also a way of preventing RGC 
apoptosis and this allows most of the RGC to survive for a long time post 
axotomy (6,7). However, in general the number of surviving RGC and the time 
of onset of apoptosis depend on the distance between the eye and the site of 
axonal injury. So, an injury close to the eye will cause a more rapid and 
extensive RGC death than an injury that is located further away from the eye (8).  
1.3.2 Cell Extrinsic Inhibitors of Axon Growth  
Although it is important that RGC do not die after injury it is crucial for CNS 
regeneration that the axotomized RGC start to grow axons again to re-connect 
with their corresponding counterparts. Elements in the extracellular environment 
of the CNS suppress axon growth, in particular those derived from myelin (9), 
the meningoglial scar (10) and the perineuronal net (11). RGC axons are 
covered in myelin that is produced by oligodendrocytes. It forms a sheath 
around the axons to increase the speed of nerve impulse conduction. Myelin-
derived proteins that act as axon growth inhibitory molecules include Nogo-A 
(12), myelin-associated glycoprotein (MAG) (13) and oligodendrocyte-myelin 
glycoprotein (OMgp) (14) (Figure 1). These proteins bind to the Nogo receptor 
complex that consists of NgR1, Lingo-1 (15) and p75NTR (16) or TAJ/TROY 
(17). This interaction leads to inhibition of axon growth by inducing growth cone 
collapse via the RhoA pathway (14,18) (Figure 1). In addition, other receptors 
and ligands of myelin-derived proteins involved in inhibition of axon growth such 
as leucine-rich, glioma-inactivated (LGI) gene product (19) and G-protein-
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coupled receptor 50 (GPR50) (20) have been recently identified. The 
meningioglial scar that generally forms after CNS injury is considered as both a 
physical and biochemical barrier of axon growth (10). Within the scar and the 
perineuronal net are proteoglycans that are major inhibitors of axon growth (21). 
Proteoglycans, such as chondroitin sulphate proteoglycans (CSPG), directly 
interact with receptor protein tyrosine phosphatase σ (RPTPσ) to signal axonal 
growth inhibition by the same RhoA-signalling cascade (22). 
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Fig 1. Nogo-A, myelin-associated glycoprotein (MAG) and oligodendrocyte-myelin glycoprotein 
(OMgp) interact with the Nogo receptor complex consisting of NgR1, Lingo-1 and p75NTR or 
TROY to signal neurite outgrowth inhibition. The signal is send into the cell via p75NTR or 
TROY to convert the inactive form of RhoA into the active form. Activation of RhoA triggers 
numerous downstream events that eventually lead to growth cone collapse. 
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Several strategies to overcome axon growth inhibition have been investigated, 
such as expressing a dominant-negative form of the Nogo receptor. However, 
supressing the receptor did not show beneficial effects without coincident 
stimulation of axon growth (23). In addition, other research has demonstrated 
that counteracting inhibition is not enough to stimulate extensive axon 
regeneration (24). One reason for that might be that, even when a few inhibitors 
are knocked out, others will still be functioning and inhibiting axon regeneration. 
Another reason might be that the low intrinsic growth potential of CNS neurons 
still restrict axon regeneration even if all inhibitory factors can be overcome.   
1.3.3 Growth Potential of RGC 
As the PNS is capable of axon regeneration, research has been carried out with 
peripheral nerve grafts implanted into the vitreous body of the eye to identify key 
regeneration factors. The grafts led to expression of growth-associated protein 
GAP-43 in RGC (25) and even enabled regeneration of axons through the ON 
(26). The PNS graft contained Schwann cells and numerous macrophages as a 
result of leaving the graft in situ for a week before transplantation. Factors 
secreted by Schwann cells or macrophages could have been responsible of the 
excessive axon outgrowth.  
An equal amount of axon regeneration from RGC after ON injury was detected 
by simply injuring the lens (27,28). Leon et al. discovered that the lens injury 
was accompanied by an influx of activated blood borne macrophages into the 
eye (27). Intravitreal injections of a pro-inflammatory agent called Zymosan 
generated even stronger axon regeneration than a peripheral nerve graft or lens 
injury (27,29). These results suggest that macrophage-derived factors can play 
   7 
  Introduction      
a key role in promoting axon regeneration in the CNS. The macrophage-derived 
growth factor that was involved in RGC axon regeneration was identified to be 
oncomodulin (30,31). Oncomodulin binds to a RGC cell surface receptor with 
high affinity and specificity. When oncomodulin in addition to cAMP was 
intravitreally injected, axon regeneration was almost as extensive as that seen 
with injection of macrophages (30). cAMP on its own, however, had little effect 
on axon regeneration, which indicates that cAMP’s effect on axon regeneration 
is mediated by oncomodulin (32). 
 
Administration of the ciliary neurotrophic factor (CNTF) also led to RGC axon 
regeneration and increased RGC survival (33). Moreover, a combination of 
other neurotrophic factors delivered intravitreally induced robust regeneration of 
RGC axons after injury (34). This suggests that axons need to overcome a 
signalling threshold in order to grow and that there is a final common pathway 
that induces growth.  
1.4 PTEN/mTOR Pathway 
Most of these above named growth stimulatory factors activate mTOR. An 
alternative way to generate RGC axon regeneration is by directly modulating the 
PTEN/mTOR pathway. This pathway regulates cell growth by modulating 
protein synthesis and its perturbation is associated with numerous diseases, 
such as Peutz-Jegher’s syndrome, tuberous sclerosis complex (TSC) and 
cancer (35). This pathway is triggered by activation of receptor tyrosine kinases, 
including Trk receptors, which activate phosphoinositide 3-kinases (PI3K) 
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(Figure 2). PI3K converts phosphatidylinositol 4,5-bisphosphate (PIP2) into 
phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 then recruits and activates 
phosphatidylinositol-dependent kinase 1/2 (PDK1/2) that leads to activation of 
Akt. Tuberous sclerosis complex (TSC) 1 and 2 form a complex to inhibit 
mammalian target of rapamycin (mTOR) (36). However, Akt activation results in 
phosphorylation and inhibition of TSC2 that prevents the TSC complex from 
supressing mTOR activation via Ras homolog enriched in brain (Rheb) (37). 
mTOR then phosphorylates and activates its substrates, eukaryote initiation 
factor 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1) 
that lead to stimulation of protein synthesis (Figure 2).  
 
Negative regulators of this pathway are phosphatase and tensin homolog 
(PTEN), RTP801 (also known as Redd1) and, as described above, TSC1/2. 
PTEN inhibits this pathway by antagonising PI3K when catalysing the change 
from PIP3 to PIP2 (38). RTP801 blocks activation of mTOR by modulating the 
activity of the TSC1/2 complex (39). So, if PTEN, RTP801 or TSC are active 
they hinder protein synthesis and therefore reduce cell growth (Figure 2). 
Therefore, these proteins may be suitable targets for inhibition in order to 
activate mTOR and stimulate disinhibited RGC axon growth in the ON.  
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Fig 2.  The PTEN/mTOR pathway regulates cell growth by modulating protein synthesis. The 
pathway is triggered by activation of PI3K via receptor tyrosine kinase (RTK).  PI3K converts 
PIP2 to PIP3. This step is antagonised by PTEN. PIP3 recruits PDK that will activate Akt. Akt 
can then inhibit TSC, an inhibitor of mTOR. When mTOR is active it phosphorylates its 
substrates to induce protein synthesis. RTP801 is a protein that is activated by stressors such 
as DNA damage and hypoxia. It positively modulates the activity of TSC to prevent protein 
synthesis.   
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1.5 mTOR/PTEN Pathway in RGC Axon 
Regeneration  
 
1.5.1 mTOR Activation 
When mTOR is active it phosphorylates a number of different substrates that 
result in protein translation and ribosome biogenesis (40). In adult RGC, active 
mTOR levels are highly reduced compared to those in embryonic neurons. In 
addition, RGC axotomy reduces the levels of active mTOR even further. 
Deleting PTEN which is, as mentioned above, an upstream inhibitor of mTOR 
results in raised levels of phosphorylated S6 and axon regeneration. When 
rapamycin, an inhibitor of mTOR, is administered into PTEN-deleted mice, RGC 
axon regeneration is largely abolished (41). These results indicate that mTOR is 
a key component of axon regeneration in the CNS.   
1.5.2 Inhibiting PTEN 
Inhibition of PTEN leads to accumulation of PIP3 and eventually to activation of 
Akt, which in turn inhibits TSC and activates mTOR. Conditional deletions of 
PTEN and several other growth control genes such as, Rb and p53, were 
performed and RGC survival and axon regeneration were monitored. PTEN 
exhibited the strongest effect on RGC survival and axon regeneration out of the 
tested growth genes (41). Combining intraocular inflammation, cAMP elevation 
and deletion of PTEN resulted in the best so far documented long-distance RGC 
axon regeneration. In fact this specific combination increased levels of axon 
regeneration ~10-fold compared to PTEN deletion or treatment with Zymosan on 
its own (32).  
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1.5.3 TSC Deletion 
TSC constitutes TSC1 and TSC2 that together form a complex to regulate cell 
growth (42). Akt phosphorylates TSC2, which stops the inhibitory effect of TSC 
on Rheb. Rheb can then activate mTOR (43). Research on over-expressing 
TSC in hippocampal neurons showed decreased axon growth (44). In 
comparison to that, knock-down of either TSC1 or TSC2 increased the number 
of neurons with several axons (44). Performing a conditional knockout of TSC1 
in a mouse model resulted in high levels of p-S6 in injured RGC. The survival 
rate of RGC after injury was higher and axon regeneration was significantly 
enhanced in TSC-deleted mice compared to wild-type mice. However, the 
regenerative potential of RGC neurons in TSC-deleted mice was slightly lower 
than that in PTEN-deleted mice (41). This suggests that, despite mTOR 
signalling, other proteins regulated by PTEN also contribute to axon 
regeneration. Nevertheless, TSC deletion did enhance RGC survival after 
axotomy and induced axon regeneration. 
 
1.5.4 Modulating RTP801 Expression 
RTP801 supresses the activation of mTOR via release of TSC2 from the 14-3-3 
protein (45). It is induced by a variety of factors, including DNA damage, 
oxidative stress, hypoxia and energy depletion (46-48) (Figure 2). Up-regulation 
of RTP801 in postmitotic neurons promoted apoptosis (49) Whereas, down-
regulation of RTP801 seemed to have an anti-apoptotic effect on RGC in a 
mouse model of retinopathy (50). Also, research with neuroprogenitor cells 
shows that knockdown of RTP801 increased levels of p-S6 (51). Increased 
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levels of p-S6 indicated that inhibiting RTP801 might lead to increased cell 
growth and therefore axon regeneration.  However, there has been no specific 
research carried out so far that shows that down-regulation of RTP801 in 
neurons also leads to axon regeneration. 
1.5.5 Targeting RTP801 with siRNA in RGC 
Using small interfering RNA (siRNA) as a method for RNA interference (RNAi) 
has become the method of choice to silence specific genes. It is performed in 
two main steps. The first step is the entrance of double stranded (ds) RNA into 
the cell where the enzyme Dicer chops it into smaller pieces, i.e. siRNA. siRNA 
is around 21-23 nucleotides long. The second step is the delivery of siRNA by 
Dicer to the RNA-induced silencing complex (RISC), which has RNase activity 
and uses the antisense siRNA strand to target mRNA to silence it (52). dsRNA 
has been successfully used in plants, worms and Drosophila to silence genes. 
However, in mammals dsRNA induced non-specific protein inhibition via an 
antiviral defence mechanism induced by interferon (IFN) (53). To prevent this, 
synthetic siRNA was developed that can avoid the initial antiviral-defence 
mechanisms while still being able to induce gene silencing (54).  
Interfering with gene expression via RNAi is in a pre-clinical trial stage for 
neurodegenerative diseases at the moment and has shown some very 
promising results (55).  
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2. OBJECTIVES 
The mTOR pathway is involved in regulation of cell growth and modulation of 
this pathway and has shown to enhance CNS axon regeneration. Data on a 
protein that seems to be an important regulator of the mTOR pathway, called 
RTP801, has not been published yet in association with CNS axon regeneration. 
In this study we want to investigate whether inhibiting RTP801 with siRNA, 
induces axon regeneration in rat RGC in vitro and in vivo. In addition, RGC will 
be treated with reagents that inhibit caspase-2 to prevent RGC apoptosis. We 
predict that inhibiting caspase-2 and RTP801 in RGC will increase RGC survival 
and enhance neurite growth in vitro and axon length in vivo.   
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3. MATERIALS AND METHODS 
3.1 In Vitro 
 
Unless otherwise stated reagents were obtained from Sigma-Aldrich (Poole, UK). 
3.1.1 Retinal Dissection 
 
To generate a culture of isolated retinal ganglion cells, eyes from Sprague 
Dawley (SD) rats (~200-250g) were used. Animals were sacrificed by rising 
concentrations of carbon dioxide (CO2) in accordance with the UK Animals 
(Scientific Procedure) Act 1986. 
  
The eyes were dissected out of the orbit with small dissection scissors and 
washed in cold sterile phosphate buffered saline (PBS, Gibco, Paisley, UK). 
Under a light microscope (Kyowa Tokyo) each eye was dissected individually 
under aseptic conditions. The eye was opened by puncturing the cornea with a 
scalpel and by cutting around the ora serrate with fine scissors. The cornea, 
lens and vitreous body was then removed with forceps to gain access to the 
retina. The retina was gently pulled apart from the loosely associated choroid 
with forceps and fully liberated by optic nerve excision (Figure 3).  
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Fig 3.  Anatomy of a rat’s eye  (Source of image: http://www.ratbehavior.org/Eyes.htm) 
 
3.1.2 Retinal Culture 
 
Four retinae were combined for each experiment and dissociated using a papain 
dissociation kit (Worthington Biochemicals, New Jersey, USA). Directly after 
removing the retinae from each eye, they were placed in a papain solution 
containing deoxyribonuclease I (DNase I) and chopped into small pieces with 
fine scissors. The solution was then incubated at 37°C in a humidified 
environment containing 5% CO2 for 90 minutes. The cap of the tube was 
loosened to allow circulation of air. After the given time the tissue was triturated 
by pipetting up and down to generate a suspension of dissociated cells. The 
suspension was then placed into a 15ml Falcon tube and centrifuged at 300g for 
5 minutes at 21°C. The supernatant was removed and the cells re-suspended in 
a solution containing 1.35ml Earle’s Balanced Salt Solution (EBSS), 150µl of 
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reconstituted albumin ovomucoid inhibitor (AOI) and 75µl DNase I. The cell 
suspension was layered on top of 2.5ml AOI to create a discontinuous density 
gradient and centrifuged at 70g for 6 minutes at 21°C. After removal of the 
supernatant the cells were re-suspended in Neurobasal-A (NBA) supplemented 
with B27 supplement, L-Glutamine (200mM) and Gentimicin. A haemocytometer 
was used to calculate the number of live cells; these cells were subsequently 
plated at a density of 250 x 103 cells per well in laminin (20µg/ml) coated 
chamber slides (BD Biosciences, Oxford, UK). Cells were incubated for 1 day 
before administering the relevant treatment (Table 1).  
3.1.3. Transfection of Retinal Culture 
 
 Treatment groups Concentration Company 
1 Lipofectamine  5µl/ml Invitrogen 
2 siRTP801* 20nM QBI Enterprises 
3 siRTP801* 
CNTF 
20nM 
10ng/ml 
QBI Enterprises 
PeproTech 
4 siRTP801* 
CNTF 
Z-VDVAD-FMK (caspase-2 
inhibitor) 
20nM 
10ng/ml 
100nM 
QBI Enterprises 
PeproTech 
R&D Systems 
5 CNTF 10ng/ml PeproTech 
6 Untreated control n/a n/a 
Table 1.  Types of treatment for retinal culture. * Length and sequence of siRTP801 is not 
available as it is currently involved in clinical trials  
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Retinal cultures were treated 1 day after set up. Three wells were used for one 
treatment group per culture. Lipofectamine 2000 (Invitrogen, Paisley, UK) was 
used to transfect RGCs with siRTP801 (QBI Enterprises, Ltd, Ness Ziona, 
Israel).  
 
For treatment groups 2, 3 and 4, equal volumes of siRTP801 (1µl) and 
Lipofectamine (1µl) were added to 99µl of Opti-MEM and incubated separately 
for 20 minutes at room temperature. At the end of the designated time, both 
solutions were mixed together and left for another 20 minutes at 37°C. For 
treatment group 1, 1µl Lipofectamine and 199µl Opti-MEM were incubated for 
20 minutes at 37°C. After supplemented NBA had been removed from the cell 
culture, 200µl of either the siRTP801-liposome or Lipofectamine mixture were 
added to a well. Treatment groups 5 and 6 were treated with 200µl Opti-MEM 
(Table 1). Cultures were then incubated at 37°C in a humidified environment 
containing 5% CO2 for 5 hours.  
After 5 hours had elapsed, the transfection solution was removed and either 
500µl of supplemented NBA for treatment group 1, 2 and 6, supplemented NBA 
and CNTF (PeproTech, London, UK) for treatment group 3 and 5, or 
supplemented NBA, CNTF and Caspase (Casp)-2 inhibitor (R&D Systems, 
Oxfordshire, UK) for treatment group 4 was added pre-warmed to 37°C per well 
(Table 1). The cultures were then incubated for further 2 days prior to analysis.  
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3.1.4 Immunocytochemistry  
 
After 2 days of treatment the medium of the cell culture was aspirated and cells 
were fixed for 10 minutes in 4% paraformaldehyde (PFA; TAAB Laboratories 
Berkshire, UK)  in Tris Buffered Saline (TBS; pH 7.3). After three washes in a 
beaker with TBS for 10 minutes, the cells were blocked with blocking buffer 
(Table 2) for 20 minutes. Each well was then treated with 150µl of a monoclonal 
mouse antibody against βlll-tubulin and monoclonal rabbit antibody against 
phosphorylated (phospho) mTOR (Cell Signalling, Herts, UK) or polyclonal 
rabbit antibody against phospho-mTOR (Abcam, Cambridge, UK) at a 1:200 
dilution for 1 hour. All antibodies were diluted in antibody dilution buffer (Table 2). 
After 1 hour, chamber slides were washed 3 times in a beaker with TBS for 10 
minutes. Secondary antibodies, Alexa Fluor 488 goat anti-rabbit IgG and Texas 
red goat anti-mouse IgG (both Molecular Probes, Invitrogen, Paisley, UK), were 
then applied in a 1:400 dilution and incubated for 1 hour covered by aluminium 
foil to prevent bleaching of fluorescence. Chamber slides were washed 3 times 
in a dark beaker containing TBS for 10 minutes. The chamber was then 
removed and slides were mounted in Vectashield with DAPI (Vector 
Laboratories, Peterborough, UK). Slides were viewed with an epi-fluorescent 
microscope and Axiovision software was used to capture images (both Carl 
Zeiss MicroImaging, LLC, Thornwood, NY).  
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Solutions Reagents 
Tris Buffered Saline (TBS) 50mM Tris-HCl, 150mM NaCl, Trizma 
base in milli-Q water 
Blocking Buffer 3%Bovine serum albumin (BSA), 1% 
TritonX inTBS 
Antibody Dilution Buffer 3%BSA, 0.5% Tween20 in TBS 
Table 2.  Solutions for immunocytochemistry  
3.1.5 Statistical Analysis 
 
Each experiment was performed at least in duplicate on separate occasions. For 
cell analysis three wells containing the same treatment were each separated 
into 9 equally sized squares. One image was randomly taken per square using 
an epi-fluorescent microscope and Zeiss camera and analysed using Axiovision 
software (Carl Zeiss MicroImaging, LLC, Thornwood, NY). Data from the images 
was averaged and plotted as graphs. No statistical analysis was carried out as 
only two independent experiments were performed.  
3.2 In Vivo 
 
3.2.1 Surgical Procedure 
 
The study used three adult Sprague Dawley rats (~150-250g) in each 
experimental and control group. All procedures were carried out in accordance 
with regulations of the UK Animals (Scientific Procedures) Act 1986 under a 
home office license. Optic nerve crush (ONC) surgeries were performed by 
Professor Martin Berry, intravitreal (ivit) injections were performed by Jenna 
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O’Neill and anaesthesia/analgesia were administered by various members of 
the Molecular Neuroscience Group. All procedures were observed by myself. 
The animals were initially anaesthetised with 4% isoflurane (Abbott Laboratories 
Ltd, Kent, UK); the dose was then reduced to 3% and maintained at this level 
throughout the procedure. Animals received a subdermal injection of the 
analgesic Buprenorphine (National Veterinary Supplies, Stoke-on-Trent, UK) at 
a dose of 0.03mg/kg prior to surgery. A lubricant was also applied to the cornea 
to prevent dehydration (Lacri-Lube, Allegan, High Wycombe, UK).   
3.2.2 Optic Nerve Crush  
 
The experimental and control group both underwent bilateral ONC at the start of 
the study.  After the rat had been anaesthetised, the head was shaved and the 
rat placed into a David Kopf stereotaxic instrument. A central rostro-caudal 
incision was made in the skin on top of the skull. To expose the orbital margin, 
the skin was slightly pulled over the upper lid and the fascia was mobilised. A 
vertical incision was made into the temporalis muscle and the incision was 
continued rostrally of the orbital margin. Care was taken to ensure that the 
supraorbital vessels did not get injured. Prior to cutting through the supraorbital 
nerve, the vessels around the nerve were crushed to avoid bleeding. The 
Harderian gland was exposed by removing its capsule and moved rostrally to 
access the ON. To expose the ON, retractors were inserted between the ON 
and Harderian gland and between the medial rectus muscle and ON. The 
retractor bulbi muscle and the dural sheath around the ON was then cut to 
access the ON. Care was taken to maintain the integrity of the central retinal 
artery that runs through the dural sheath. The ON was then crushed 2mm distal 
   21 
  Material and Method      
from the eyeball (Figure 4). After the crush the retractors were removed and the 
rectus muscles, Harderian gland and skin were placed back to their original 
position. The same procedure was then carried out on the second ON. After two 
successful ONCs the skin margins were sutured.   
3.2.3 Lens Injury  
Immediately after the ONC, the experimental and control groups received 
bilateral lens injury. The tip of a 19 gauge needle was inserted through the 
sclera immediately posterior to the ora serrate and perpendicular to the axis of 
the ON. The needle tip was then moved across the surface of the lens to induce 
injury to the lens capsule. 
3.2.4 Intravitreal Injections 
A glass micropipette was loaded with 10µl of the relevant treatment (Table 3) 
and attached to a syringe. The micropipette was then inserted into the vitreous 
body through the sclera immediately posterior to the ora serrate (Figure 4). The 
solution was injected slowly into the vitreous body to ensure adequate diffusion. 
Both eyes of each animal in the experimental (n=3) and control group (n=3) 
received injections stated below (Table 3). After the first injection, injections 
were carried out every 8 days over the experimental period (three times in total). 
Animals were sacrificed by rising concentrations of CO2 after 24 days.       
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 Treatment Volume Concentration 
Experimental Group siRTP801* 
siCasp-2* 
5µl 
5µl 
20µg/ml 
20µg/ml 
Control Group siEGFP* 10µl 20µg/ml 
* QBI Enterprises, Ltd, Ness Ziona, Israel  
Table 3.  Treatment groups for in vivo experiment 
 
 
 
Fig 4.  ON was crushed 2mm distal from the eyeball. Lens injury was induced just after ONC. 
Ivit injections were performed every 8 days. Solutions for both groups were injected into the 
vitreous body. (Source of image: Leon et al., 2000)  
 
3.2.5 Tissue Preparation for Histology 
On day 24 post-ONC, animals were given a lethal overdose of CO2 and 
perfused intracardially with 300ml PBS followed by 300ml 4%PFA in PBS. The 
ON segments, with the chiasm still attached, were dissected free from 
connective tissue and post-fixed in 4%PFA at 4°C overnight. The ON were then 
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placed sequentially through sucrose gradients to cryoprotect the tissue. This 
involved placing the tissue in 30%, 20% and 10% sucrose solutions in PBS at 
4°C overnight. The nerves were then embedded in OCT embedding medium 
(R.A. Lamb Laboratory, Cheshire, UK). ON sections of 15µm were cut 
longitudinally on a cryostat (Bright Instrument Company, Huntingdon, UK). The 
sections were thaw-mounted onto coated glass slides (Leica Microsystems, 
Peterborough, UK) and dehumidified at 37°C overnight to increase adhesion. 
Slides were kept at -80ºC for long-term storage.  
3.2.6 Immunohistochemistry  
 
Due to limited time one ON instead of both ON per animal were stained and 
analysed. The sections were defrosted at room temperature and washed in 
rinsing buffer (Table 4) three times for 5 minutes. Rinsing buffer around the ON 
was aspirated and a hydrophobic pen was used to draw a circle around each 
section. Sections were then incubated with 200µl blocking buffer (Table 4) in a 
humidified chamber for 1 hour at room temperature. After the time had elapsed, 
sections were treated with 200µl of a monoclonal mouse antibody against 
neuronal growth-associated protein GAP-43 (Invitrogen, Paisley, UK) and 
polyclonal rabbit antibody against Laminin (Sigma-Aldrich) at a 1:500 dilution at 
4°C in a humidified chamber overnight. Sections were washed in rinsing buffer 
three times for 5 minutes. Secondary antibodies Alexa Fluor 488 goat anti-
mouse IgG and Alexa Fluor 594 goat anti-rabbit IgG (both Molecular Probes, 
Invitrogen, Paisley, UK) were then applied in a 1:500 dilution and incubated at 
room temperature for 1 hour in a dark humidified chamber to prevent bleaching 
of fluorescence. Sections were washed in rinsing buffer three times for 5 
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minutes and then mounted in Vectashield with DAPI (Vector Laboratories, 
Peterborough, UK). They were viewed with an epi-fluorescent microscope and 
the Axiovision software was used to capture images (both Carl Zeiss 
MicroImaging, LLC, Thornwood, NY).  
 
Solutions Reagents 
10mM PBS PBS tablets in milli-Q water 
Rinsing Buffer 0.1% TritonX in PBS 
Blocking Buffer 10% New-born goat serum, 3% BSA in rinsing 
buffer 
Antibody Dilution Buffer 3% BSA in rinsing buffer 
Table 4.  Solutions for immunohistochemistry 
 
3.2.7 Statistical Analysis  
 
Axon growth was quantified by counting the number of GAP-43 positive axons 
within 200-500µm, 500-1000µm, 1000-1500µm and 1500-2000µm distal to the 
crush site.  
An N value of 3 was obtained. The Student T Test was carried out and a P value 
of < 0.05 was considered as significant.   
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4. RESULTS 
4.1 In Vitro Studies 
 
4.1.1. Identification of mTOR Activation in RGC 
 
To investigate whether inhibiting RTP801 activates the mTOR pathway and 
therefore leads to RGC axon regeneration, primary retinal cultures containing 
RGC were treated with siRTP801 to knock down gene expression. Due to a 
limited amount of time the in vitro experiments could only be carried out in 
duplicate. RGC were characterised by being immunopositive for βIII-tubulin, 
spherical, having no more than two neurites and large nuclei counterstained with 
DAPI.  To demonstrate mTOR activation RGC were stained with an antibody 
against phospho-mTOR. For most of the experiments phospho-mTOR from Cell 
Signalling was used. This antibody stained βIII-tubulin positive RGC extremely 
weakly producing a signal no greater than the no primary control (Figure 5). As 
such, the generated images were deemed to be immunonegative and this 
antibody was not used in future experiments. The phospho-mTOR antibody from 
Abcam was used as an alternative and generated stronger βIII-tubulin positive 
RGC immunostaining (Figure 5). However, both antibodies stained all βIII-
tubulin positive RGC irrespective of treatment so that a differentiation between 
an untreated control and siRTP801 treated RGC was not possible. Therefore, 
both antibodies were not used to demonstrate activation of mTOR. Instead the 
functional outcome (i.e. RGC survival and neurite outgrowth) was used to 
determine if the mTOR pathway had been activated by siRTP801 treatment. 
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Fig 5.  βIII-tubulin positive RGC were immunostained with two different antibodies against 
phospho-mTOR. Phospho-mTOR from Cell Signalling produced an extremely weak signal. 
Phospho-mTOR from Abcam produced a stronger signal that correlated with the βIII-tubulin 
positive RGC. The no primary control was used as a comparison and to asses antibody 
specificity. Scale bar, 50µm  
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4.1.2 The Effect of siRTP801, CNTF and Caspase-2 Inhibitor on 
RGC Survival  
 
Since there is no data regarding the effect of inhibiting RTP801 on RGC survival, 
primary retinal cultures were treated with siRTP801 alone or in combination with 
CNTF or CNTF and Casp-2 inhibitor. As the experiments were only carried out 
in duplicate no statistical analysis was performed. 
 
The number of surviving βIII-tubulin positive RGC in the treatment groups (Table 
1; Lipofectamine, CNTF, siRTP801, siRTP801+CNTF and 
siRTP801+CNTF+Casp-2 inhibitor) was compared to an untreated control. All 
treatment groups tended to have high survival rates (Figure 6). Treatment with 
Lipofectamine, CNTF and siRTP801+CNTF enhanced survival (≥100%). 
Lipofectamine and CNTF treated RGC had the highest survival rates (≥125%). 
siRTP801 alone did not increase cell survival. Treatment with siRTP801, CNTF 
and Casp-2 inhibitor slightly reduced survival (90%), which was unexpected as 
caspase-2 is a pro-apoptotic enzyme (Figure 6). 
 
Overall, the treatment groups that were treated amongst other reagents with 
siRTP801 had lower survival rates compared to CNTF treated groups and only 
the siRTP801+CNTF group had higher survival rates compared to the control. It 
appears to be a trend that inhibiting RTP801 does not enhance survival. 
However, the small replicate number of each treatment group prevented the 
significance of the difference being assessed. 
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Fig 6. Mean percentage of surviving primary RGC in response to treatment with siRTP801, 
CNTF and Casp-2 inhibitor. Each experiment was performed in duplicate on separate occasions 
except treatment with Lipofectamine, which was performed three times. 
 
4.1.3.Number of RGC with Neurites 
 
Modulating the mTOR pathway in RGC in vivo by inhibiting PTEN or TSC 
significantly enhanced neurite outgrowth (41). However, the effect of modulating 
the mTOR pathway in RGC in vitro has never been reported.  
A neurite was defined as any RGC projection longer than one cell soma in 
diameter. The Lipofectamine group exhibited a slightly higher number of RGC 
with neurites compared to the untreated control. CNTF treatment enhanced 
neurite outgrowth the most out of all treatment groups. Treatment with siRTP801 
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alone did not promote neurite outgrowth and may have even caused minor 
inhibition. When siRTP801 was added in combination with CNTF, the number of 
RGC with neurites was greater than control but less than that of CNTF alone. 
The siRTP801-CNTF-Casp-2 inhibitor group induced the same level of neurite 
outgrowth (Figure 7) but caused reduced RGC survival than siRTP801 and 
CNTF treatment (Figure 6). Altogether treating RGC with siRTP801 on its own 
enhanced neurite outgrowth the least compared to all other treatment groups 
whereas treatment of siRTP801 in combination with CNTF or CNTF and Casp-2 
inhibitor enhanced neurite outgrowth.  
 
 
Fig 7. Mean number of RGC with neurites in response to treatment with siRTP801, CNTF and 
Casp-2 inhibitor. Each experiment was performed in duplicate on separate occasions except 
treatment with Lipofectamine, which was performed three times. 
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4.1.4 Stimulation of RGC to Increase Neurite Length  
 
Neurite length was measured using Image Pro Software to investigate whether 
activation of mTOR via siRTP801 increased neurite length. The untreated 
control group and the Lipofectamine group both induced similar low levels of 
neurite outgrowth (Figure 8). This indicates that the Lipofectamine reagent did 
not have an adverse effect on neurite outgrowth and survival. CNTF treatment 
appeared to enhance RGC survival and neurite outgrowth (Figure 6,7,and 8). 
siRTP801+CNTF enhanced neurite length more than siRTP801 and CNTF 
alone. In fact treatment with siRTP801+CNTF increased neurite length ~ 2-fold 
compared to untreated and Lipofectamine controls. The combination of 
siRTP801, CNTF and Casp-2 inhibitor had the greatest impact on neurite length 
inducing a ~ 3-fold increase compared to untreated and Lipofectamine controls 
and a ~ 2-fold increase compared to CNTF and siRTP801 group (Figure 8). 
Figure 9 illustrates examples of neurite length of βIII-tubulin positive RGC 
stimulated by each treatment group. RGC are stained with βIII-tubulin and nuclei 
are stained with DAPI. As can be observed from Figure 6, the longest neurites 
were detected in RGC cultures treated with siRTP801+CNTF+Casp-2 inhibitor 
compared to untreated control and Lipofectamine groups, which contained βIII-
tubulin positive RGC without neurites.  
Although treatment with siRTP801+CNTF+Casp-2 inhibitor hardly enhanced 
βIII-tubulin positive RGC survival and outgrowth, it did however, enhance neurite 
length strongly compared to the other treatment groups in vitro. Therefore, the 
combination of caspase-2 and RTP801 inhibition was also tested in vivo to 
evaluate effects on RGC axon regeneration. 
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Fig 8. Mean length of longest neurite per βIII-tubulin positive RGC in response to treatment 
with siRTP801, CNTF and Casp-2 inhibitor. Each experiment was performed in duplicate on 
separate occasions except treatment with Lipofectamine, which was performed three times. 
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Fig 9.  Examples of βIII-tubulin positive RGC counterstained with DAPI that have been treated 
with various treatments. Scale bar, 50µm. 
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4.2 In Vivo Studies 
 
To investigate the effect of stimulating mTOR signalling by inhibiting RTP801 
and prolonging RGC survival using siCasp-2 (4) on axon growth in vivo, 
siRTP801 and siCasp-2 were injected into the vitreous body of adult rats every 8 
days for 24 days after they received ONC with a lens injury to induce RGC axon 
outgrowth (27,29). Control animals received ONC and lens injury but were 
injected with a non-targeting siRNA (siEGFP).  
 
To determine whether siCasp-2 prevented apoptosis in RGC, GAP-43 positive 
axons in the proximal segment of the ON, before the site of ONC, were counted 
in the experimental and control groups. Axons were counted along a vertical line 
drawn across the ON (200µm before the site of ONC). To analyse whether 
blocking RTP801 and activating the mTOR pathway enhanced axon elongation 
through the lesion site, GAP-43 positive axons were counted in the distal ON 
post-ONC. Axons were counted in an area 200-500µm, 500-1000µm, 1000-
1500µm and 1500-2000µm distal to the site of ONC.   
As it was not possible to specify continuous axons, as they go in and out of the 
plane of view, each GAP-43 positive axon segment (Figure 10; see white 
arrows) was counted and defined as one axon.  
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Fig 10. Part of an ON distal to the site of ONC. 
Each GAP-43 positive axon (indicated by a 
white error) was counted to determine the 
regenerative potential of modulating the mTOR 
pathway via siRTP801 
 
 
 
 
4.2.1 Optic Nerve Regeneration In Vivo 
At 24 days after the ONC, levels of axon regeneration were determined by GAP-
43 immunohistochemistry. Treatment with siRTP801 and siCasp-2 enhanced 
lens injury-induced survival of RGC axons proximal to the site of ONC as 
expected (Figure 11.A.I and 12). Treatment with siEGFP also appeared to 
enhance RGC survival (Figure 11.B.I and 12). It was less compared to the 
experimental group but no significant difference between both groups was 
detected (p >0.05). Furthermore, both groups showed a similar amount of axon 
regeneration distal to the site of ONC (Figure 11). Higher numbers of GAP-43 
positive axons were detected in the centre of the ON of the experimental group 
(Figure 11.A.II). In the control group more axons were present at the margins of 
the ON than the centre at the same distance distal to the ONC (Figure 11.B.III).  
Axons that were growing along the edges of the ON grew a relatively long 
distance in both groups (Figure 11.A.IV and 11.B.IV). Few axons in the centre of 
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the ON grew longer distances than axons present at the margins (Figure 11.A.V 
and 11.B.V).  
Overall, treatment with siRTP801 and siCasp-2 slightly enhanced lens injury-
induced survival of RGC axons but with no significant difference to treatment 
with siEGFP. Furthermore, no significant difference between both treatment 
groups was detected distal to the site of ONC (p > 0.05) (Figure 13).   
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Fig 11.  Longitudinal sections of ON immunostained to detect GAP-43 positive axons proximal 
and distal to the injury site (asterisk) 24 days after ONC. Rats were injected with siRTP801 and 
siCasp-2 (A) or with siEGFP (B) after lens injury and ONC, Scale bar, 200µm. X40 
magnifications of nerves  (A I-IV) and (B I-IV) Scale bar for inserts, 30µm. 
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Fig 12. Quantification of RGC survival by counting GAP-43 positive axons 200"m proximal to 
the site of the ONC. Values are means ± SEM. n=3 
 
Fig 13.  Quantitation of axon regeneration by counting GAP-43 positive axons distal to the site 
of the ONC. Values are means ± SEM. n=3 
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4.2.2 Response of Individual Animals to siRTP801 and siCasp-2 
 
Since animals responded to the treatment in different ways, we analysed the 
data from individual animals to understand our findings from this study better. 
Animal 1 in the experimental group responded very well to the treatment with 
over 40 axons reaching 1000µm and 15 axons reaching 1500µm and beyond. 
Animal 2 and 3 on the other hand showed a weak or minimal response to the 
treatment with siRTP801 and siCasp-2 (Figure 14A). A similar variability 
amongst individual animals was also observed in the control group. In this group, 
animal 1 showed a stronger reaction to the treatment than animal 2 and 3 but 
the variation between the animals that responded to those that did not is less 
compared to the experimental group (Figure 14B). 
The number of GAP-43 positive axons from the responding animal (Animal 1, 
Figure 14A) in the experimental group was ~ 2-fold higher at 1000-1500µm and 
1500-2000µm compared to the responding animal (Animal 1, Figure 14B) from 
the control group. Although the average number of GAP-43 positive axons from 
all animals of each group does not show great difference, the difference 
between axon regeneration from the responding animals of each group is much 
greater.  
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Fig 14. Quantitation of axon regeneration in individual animals by counting GAP-43 positive 
axons distal to the site of the ONC. Every eight days animals received injections with siRTP801 
and siCasp-2 (A) and siEGFP (B). 
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5. DISCUSSION 
 
After injury to the CNS, axon regeneration is crucial to prevent irreversible 
neurological deficits. The pathophysiological process of CNS injury is still very 
limited and hence prevents the discovery of novel treatments for people with 
CNS injury. Several animal studies have shown that axon regeneration is 
possible (26,27,29,32). However, for treatment in humans it is necessary that 
the reagents used for axon regeneration are safe and affordable.  
 
Treatment for various diseases with siRNA has gained more and more 
interest. A siRNA, against human RTP801 (PF-655) provided by the same 
company (Quark Pharmaceuticals) as the siRNA used for this study, is 
currently in a Phase II clinical trial for treatment of wet age-related macular 
regeneration (AMD) and diabetic macular oedema (DME) 
(http://www.quarkpharma.com/qbi-en/products/53/). As this siRNA shows 
promising results for AMD and DME the overall aim for this study was to 
investigate the effect of siRTP801 on axon regeneration in vitro and in vivo. 
 
5.1 In Vitro Studies 
 
5.1.1 Activation of the mTOR Pathway  
 
Phospho-mTOR antibodies from two different companies were used to 
immunostain βIII-tubilin positive RGC to determine whether mTOR had been 
activated by inhibiting RTP801. The phospho-mTOR antibody from Cell 
Signalling immunostained βIII-tubilin positive RGC more weakly than the
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 phospho-mTOR antibody from Abcam and staining could not be 
distinguished from a no-primary control. Although the phospho-mTOR 
antibody from Abcam immunostained βIII-tubilin positive RGC strongly, there 
was no difference in staining intensity between untreated controls and 
siRTP801 treated RGC. To be able to determine whether mTOR has been 
activated a quantitative technique such as western blot or post-transcriptional 
regulation should be used. 
 
The reason why the untreated controls were immunopositive for phospho-
mTOR could be because of a stress response induced by tissue dissociation 
and cell culture. Therefore a positive and negative control needs to be used in 
future experiments to determine antibody specificity and levels of mTOR 
activation. Once this has been determined, each of the antibodies can be 
optimised and used or excluded from future experiments.  In addition to this, 
mTOR activation could be confirmed using an antibody targeted against 
mTOR’s substrate such as phospho-S6. Antibodies against phospho-S6 have 
been used in several studies as a reliable way to monitor activation of mTOR 
(41,51). As mTOR activation in RGC could not be determined by 
immunocytochemistry, we decided to focus on the functional outcomes 
associated with siRNA treatment. 
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5.1.2 Functional Effect of siRNA Treatment 
 
In vitro, RGC were treated with different combinations of siRTP801, CNTF 
and Casp-2 inhibitor.   
Choosing a siRNA (siRTP801) as a method to silence specific genes has 
become very popular in research and has shown promising results for 
therapeutic purposes. Treatment of RGC with siRTP801 was expected to 
enhance neurite outgrowth and to better monitor this effect a Casp-2 inhibitor 
plus CNTF were used to prevent RGC apoptosis. The Casp-2 inhibitor is a 
specific and irreversible inhibitor of caspase-2 (see instruction of R&D 
Systems, www.rndsystems.com/pdf/fmk003.pdf). It is also cell permeable and 
therefore does not require a transfection agent (Lipofectamine), as does 
siRTP801. CNTF enhances RGC survival but also stimulates neurite 
outgrowth (33,56).  
To test the functional effect of siRTP801 on neurite length, RGC cultures were 
treated with either siRTP801, siRTP801 and CNTF or siRTP801,CNTF and 
Casp-2 inhibitor. CNTF was used as positive control whereas Lipofectamine 
was used as a transfection control. An untreated group was included as 
negative control. 
5.1.3 RGC Survival In Vitro 
 
Treating retinal cultures with CNTF enhanced RGC survival rates whereas 
treatment with siRTP801 alone and in combination with CNTF and Casp-2 
inhibitor had lower survival rates. CNTF and siRTP801 treatment had a 
greater effect on RGC survival than did siRTP801 alone, however this effect 
was not as great as CNTF treatment alone. It seems that siRTP801 does not 
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have a marked effect on RGC survival, which was expected. Inhibiting the 
mTOR pathway appeared to promote neurite outgrowth rather than cell 
survival. The treatment that contained Casp-2 inhibitor in addition to 
siRTP801 and CNTF had the lowest survival rate compared to the other 
treatment groups, which was unexpected as Casp-2 inhibitor and CNTF both 
prevent apoptosis (4,33). The Casp-2 inhibitor was added one day after RGC 
had been cultured. During that time RGC may have already started to die. 
Therefore, Casp-2 inhibitor might have been less effective at this point. 
However, CNTF was still present in this treatment group but the survival rate 
is still lower that treatment with siRTP801 and CNTF. This could mean that 
Casp-2 inhibitor decreased RGC survival when added later than a few hours 
after culturing, it has some adverse effects on CNTF. Nevertheless, it needs 
to be emphasised that these experiments have been repeated only two times 
so no definitive conclusions can be drawn from that.  An experiment where 
Casp-2 inhibitor is added to the RGC culture immediately after culturing and a 
day after culturing could be carried out to optimise how the inhibitor acts on 
RGC. Also, RGC could be treated with Casp-2 inhibitor and CNTF together to 
determine how those two reagents interact with each other in terms of RGC 
survival. In addition, when using a combinational treatment the dose of each 
treatment may need to be altered accordingly to have a synergistic effect. 
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5.1.4 Neurite Outgrowth In Vitro 
 
Treatment with CNTF generated the highest number of βIII-tubulin positive 
RGC with neurites compared to other treatment groups. The siRTP801, CNTF 
and Casp-2 inhibitor and the siRTP801 plus CNTF treatments both enhanced 
the number of βIII-tubulin positive RGC with neurites. siRTP801 treatment 
alone had a minimal effect on neurite outgrowth compared to the other 
treatment groups.  
CNTF induces neurite outgrowth in RGC (33), whereas siRTP801 did not. 
However, this might be because the concentration of siRTP801 was too high 
and inhibited neurite outgrowth. This could explain why there were more βIII-
tubulin positive RGC with neurites when the RGC culture was treated with 
CNTF alone than with siRTP801+CNTF and why the fewest βIII-tubulin 
positive RGC with neurites were found in the siRTP801 treatment group. 
Casp-2 inhibitor does not have a documented effect on neurite outgrowth. 
This is also demonstrated by the data in Figure 7 where there is no difference 
between siRTP801+CNTF and siRTP801+CNTF+Casp-2 inhibitor treatment 
groups.  
5.1.5 Mean Length of Longest Neurite In Vitro 
The treatment groups that contained siRTP801 enhanced neurite length the 
most compared to the untreated controls, Lipofectamine or CNTF treatment 
groups. Although CNTF greatly enhanced RGC survival and the number of 
neurites it enhanced neurite length relatively little. All the treatment groups 
that contained siRTP801 did not enhance RGC survival. In addition, treatment 
groups with siRTP801 that also contained CNTF increased the number of 
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RGC with neurites but not as much as CNTF alone. Treatment with siRTP801 
increased neurite length more than treatment with CNTF. The results indicate 
that siRTP801 does not act on RGC survival and is not as effective as CNTF 
in inducing neurite outgrowth. However, once a neurite has grown, treatment 
with siRTP801 seems to enhance neurite length. CNTF and siRTP801 
together enhance neurite length more than on its own, which indicates that 
these two reagents act together to increase neurite length. Casp-2 inhibitor 
had no effect on RGC survival or number of RGC with neurites. Although the 
treatment group siRTP801+CNTF+Casp-2 inhibitor had fewer cells that 
survived, those RGC that did survive had the most increased neurite length 
out of all treatment groups. This might be because the Casp-2 inhibitor only 
prevents cell death when RGC are primed by neurotrophic factors and able to 
grow long neurites. Overall, siRTP801 does not enhance RGC survival or the 
number of RGC with neurites, but it seems to increase neurite length, which is 
an important factor for CNS regeneration. Especially in combination with 
CNTF and Casp-2 inhibitor, siRTP801 greatly enhanced neurite length.  
5.1.6 Future Work for In Vitro Experiments 
Although the generated data seems promising as treatment with siRTP801 
enhanced neurite length, to fully come to a conclusion the experiments need 
to be repeated at least once more so statistical significance can be assessed. 
It would also be interesting to see the effect on RGC when treated with Casp-
2 inhibitor on its own or in combination with CNTF and whether the time that 
this Casp-2 inhibitor is added influences RGC survival.  
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Even though a functional effect could be detected when RGC were 
transfected with siRTP801, to confirm RGC transfection efficiency, siRTP801 
could be fluorescently tagged.  
To establish whether the gene knock down has been successful, western blot 
could be carried out to determine the presence of RTP801 or qPCR to check 
whether the mRNA for RTP801 is still present.  
Also, no specific test to determine apoptosis, such as the terminal 
deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling 
(TUNEL) staining was done. It would be good to know how many RGC were 
dying when treated with the Casp-2 inhibitor and in combination with 
siRTP801 and CNTF and when it would be best to treat RGC with Casp-2 
inhibitor.  
During the analysis for this study each well was divided into 9 squares and 
one picture was taken in the centre of each square. The cells sometimes 
cluster in certain areas of the culture well and if more pictures in one square 
had been taken, it would have generated more representative results.  
5.2 In Vivo Studies 
 
5.2.1 The Effect of siRTP801 and siCasp-2 
 
Animals from the experimental and control groups received bilateral ONC and 
lens injury; the experimental group received ivit injections of siRTP801 and 
siCasp-2, the control group received equivalent injections of siEGFP. 
Treatment with siRTP801 and siCasp-2 enhanced RGC axon number 
proximal to the site of the ONC (the measure of RGC survival) more than 
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siEGFP. This was expected as another study had demonstrated that 
treatment with siCasp-2 induces survival of RGC in vivo (4). 
The number of re-generating axons distal to the site of the ONC in the 
experimental and control group showed only slight differences, as the number 
of re-generating axons in the control group was high. This might be because 
both groups received a lens injury that causes inflammation and the release of 
neurotrophic factors. Studies have shown that inflammatory agents stimulate 
axon regeneration (27,29,32). The fact that the number of re-generating 
axons was so high in the control group makes the regenerative effect of 
siRTP801 difficult to assess. Nevertheless, a slightly higher number of axons 
were present at the most distal points to the site of ONC whereas slightly 
fewer axons were present closer to the site of the ONC when treated with 
siRTP801 and siCasp-2 compared to siEGFP. This indicates that despite 
fewer axons regenerating close to the distal site of the ONC, more axons that 
do regenerate grow longer distances when treated with siRTP801 and 
siCasp-2. These results are supported by the data generated in the in vitro 
experiment. Treating RGC with siRTP801 did not affect the survival rate or the 
number of RGC with axons but it affected the distance the axons regenerate.  
However, due to the variability in response between animals, more animals 
are needed to confirm this data. In addition to that, the number of re-
generating axons in the ON from the second eye of the examined animals 
should be quantified. Also, some of the animals developed cataracts (the 
measure of lens injury) but this was not documented for individual animals. 
The animals that had a cataract might have had a stronger inflammatory 
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reaction, which means that the axon regeneration could have been stronger 
compared to the animals without the cataracts. For the next study this should 
be documented and considered when doing the analysis.   
For further details on RGC survival the retina containing RGC could be 
immunostained and quantified.  
 
Overall, no definite conclusion can be made from this data but there is 
certainly a trend towards long distance axon regeneration initiated by 
siRTP801 transfection. Further experiments need to be carried out to confirm 
this hypothesis. 
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ABSTRACT 
Hepatic fibrosis and its end stage cirrhosis are a major health burden 
worldwide caused by sustained accumulation of extracellular matrix (ECM). 
Cell therapy with mesenchymal stem cells (MSC) could be a promising 
approach to treat hepatic fibrosis and cirrhosis. Tumour necrosis factor-like 
weak inducer of apoptosis (TWEAK) and its receptor fibroblast growth factor-
inducible 14 (Fn14) have been associated with modulating cell proliferation, 
differentiation, death and inflammation. Fn14 is highly up-regulated in the 
injured liver. Therefore, it would be important to understand how TWEAK-
dependent Fn14 signalling affects MSC. Herein we present evidence that 
unstimulated MSC express Fn14. Fn14 expression decreases in adipogenic 
cultures and stimulation with TWEAK did not seem to affect adipogenesis. A 
single experiment in addition to literature suggests that TWEAK might 
influence MSC survival, which we may investigate in the future. We further 
report high Fn14 expression on hepatic stellate cells (HSC), the main source 
of ECM. However only one donor was investigated and therefore we need to 
carry out more experiments to consolidate these results. In conclusion, 
mesenchymal cells seem to express Fn14 but how TWEAK-dependent Fn14 
signalling affects these cells is still inconclusive.  
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1. INTRODUCTION 
1.1 General Introduction to Fibrosis 
Fibrosis is a natural wound-healing response that involves regulation of scar 
formation (fibrogenesis) and degradation (fibrolysis) to acute or chronic injury 
to the liver. Fibrosis during acute injury is transient and reversible but the 
sustained signals during chronic injury lead to a several-fold increase in 
production and deposition of extracellular matrix (ECM) resulting in fibrosis 
(57). Not only the quantity of ECM but also the composition changes in the 
fibrotic liver. In the normal liver, the space of Disse contains mainly collagens 
type IV and VI but during fibrogenesis an increased deposition of collagens 
type I and III occurs (58). Hepatic stellate cells (HSC) are the main cellular 
source of ECM in hepatic fibrosis. In a healthy liver, HSC store lipid-soluble 
vitamin A metabolites (retinoids) (59) and reside in the space of Disse. 
However, following liver damage, HSC become active, loose their vitamin A 
storing capacity, start expressing α-smooth muscle actin (α-SMA), and 
transdifferentiate into myofibroblast-like cells with ECM secreting capacity 
(57,60,61) (Figure 1). Transforming growth factor-β (TGF-β) has been 
demonstrated to be the key mediator in activating HSC (62). Animal models 
have shown that inhibiting TGF-β, significantly decreases fibrosis (63). 
Nevertheless it has recently become clear that not all fibrogenic cells in the 
liver originate from HSC. Various research groups have demonstrated that 
portal fibroblasts (64), circulating fibrocytes (65) and bone marrow (66) can 
also contribute to liver fibrosis (Figure 2). 
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Fig 1.  In a normal liver HSC reside in the subendothelial space of Disse. As a result of liver 
damage, HSC transdifferentiate into proliferative myofibroblasts that secrete ECM. Continues 
accumulation of ECM leads to liver fibrosis and eventually to cirrhosis. (Source of image 68) 
 
 
 
Fig 2.  Although it was believed that all ECM-secreting myofibroblasts originate from HSC 
evidence suggest that portal fibroblasts, bone marrow, circulating fibrocytes and epithelial-
mesenchymal cell transition (67) can also transdifferentiate into myofibroblasts (Source of 
image 69) 
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1.2 Cause and Treatment of Hepatic Fibrosis 
Hepatic fibrosis and its most advanced stage, cirrhosis, can be caused by a 
number of factors including chronic infections with hepatitis B or C viruses, 
non-alcoholic steatohepatitis, toxic damage through long-term alcohol abuse 
and parasitemia (57). Cirrhosis is associated with an increased risk of liver 
failure and hepatocellular carcinoma (HCC). It represents a substantial health 
burden worldwide. In the UK over 4000 people die from cirrhosis every year 
and approximately 700 people have to have a liver transplant in order to 
survive (http://www.nhs.uk/conditions/Cirrhosis/Pages/Introduction.aspx).  
A major issue with liver transplants are that donor livers are limited and 
patients have to take toxic, immunosuppressive medications for the rest of 
their life. However, new evidence suggests that even advanced fibrosis can 
be reversible (70,71) and therefore novel strategies to treat fibrosis and 
cirrhosis should be investigated. Cell therapy with hepatocytes, embryonic 
stem cell derived hepatocytes or mesenchymal progenitor cells shows 
promising results. Preventing accumulation of ECM via blocking activation of 
HSC is another strategy with potential.  
1.3 Mesenchymal Progenitor Cells 
Mesenchymal progenitor cells (MPC) are nonhaematopoietic multipotent cells 
that can differentiate into mesenchymal and nonmesenchymal lineages. MPC 
can be isolated from various tissues in the human body. One of the best 
studied MPC are mesenchymal stem cells (MSC) that can be isolated from 
bone marrow and other tissues such as muscle and fat. Bone marrow derived 
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MSC have been successfully used in several clinical trials for therapeutic 
application in patients with cirrhosis (72-74). Another type of MPC that are 
also of interest in the pathogenesis of cirrhosis are HSC, the resident cells of 
the liver. As mentioned above, it is believed that they are the main source of 
ECM in fibrogenesis. Therefore inhibiting HSC activation or causing apoptosis 
of active HSC would provide another possible treatment option for fibrosis. 
1.4 MSC as Therapeutics for Cirrhosis 
1.4.1 MSC Can Modulate the Immune System 
MSC have been demonstrated to be an appealing source for cellular therapy 
and tissue engineering. The benefits of using MSC for therapeutic treatment 
include easy isolation and cultivation, high expansion potential and a stable 
phenotype (75,76). 
MSC in their undifferentiated state have an anti-inflammatory effect (77) and 
as inflammation often precedes fibrosis, this could be an important attribute of 
MSC for cell therapy of fibrosis. The precise mechanisms by which MSC exert 
their immunosuppressive properties are still unclear but the production of 
various growth factors, cytokines and other signalling molecules may be 
involved (77). Studies have shown that during inflammation, pro-inflammatory 
cytokines such as tumour necrosis factor-α (TNF-α) and interleukin-1 (IL-1) 
are released. One study for example demonstrated that MSC can down-
regulate inflammatory responses by secreting IL-1 receptor antagonists and 
upregulate anti-inflammatory cytokines such as IL-10 (78). Another study has 
shown that MSC can express high levels of inducible nitric-oxide synthase 
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(iNOS) and chemokines that are essential for immunosuppression (79). It is 
also believed that MSC supress inflammatory responses via cell-to-cell 
contact (80). 
 
Even though the precise mechanisms by which MSC exert their 
immunosuppressive activity are still lacking, MSC have been used clinically 
for over a decade now to treat life-threatening graft-versus-host disease 
(GvHD). Evidence suggests that MSC inhibit T cell reactivity from the donor 
liver to histocompatibility antigens of the normal tissues of the recipient during 
the treatment of GvHD (76). 
 
Besides the ability of MSC to modulate the immune system, they can also 
avoid recognition of another host’s immune system. MSC lack for example 
major histocompatibility complex (MHC) class II to avoid recognition by CD4+ 
T cells (81). This is another benefit of MSC for cell therapy as it is more likely 
that allogeneic cells will be used to repair and replace damaged tissue. 
Compared to other cells, MSC are not recognised by the recipient’s immune 
system as foreign and removed by immunocytes.  
  
1.4.2 MSC Contribute to Liver Repair 
The ability of MSC to modulate and evade the immune system is not the only 
therapeutic advantage that has been reported. Indeed as well as being 
capable of differentiating into cells from the mesenchymal lineage (82), MSC 
have been demonstrated to be capable of differentiating into hepatocyte-like 
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cells in vitro. These cells had functional characteristics of hepatocytes 
including albumin production, glycogen storage and urea secretion (83). 
However, when human MSC were directly injected into immunosuppressed 
rats with injured liver parenchyma, the differentiation efficiency into 
hepatocyte-like cells was very low (84). These results were also confirmed by 
another study using immunosuppressed mice (85). To avoid low 
differentiation efficiency in vivo MSC could be pre-differentiated before 
transplantation.  
 
Another therapeutic advantage that has been attributed to MSC is preventing 
apoptosis and stimulating proliferation of hepatocytes in injured livers (86). In 
a rat model of D-galactosamine-induced fulminant hepatic failure (FHF), 
secreted factors from MSC significantly reduced rat mortality, decreased 
hepatocellular apoptosis up to 90% and enhanced hepatocyte proliferation 
(86). Furthermore, it has been demonstrated that MSC-derived molecules can 
reduce collagen secretion and proliferation of activated HSC (75). Also, 
animal and clinical trials showed that administration of MSC can decrease 
collagen accumulation in fibrotic livers and improve liver function (87-89).  
1.4.3 Mesenchymal Stem Cells in Pathogenesis of Cirrhosis 
It has recently been demonstrated in mice and human that bone marrow-
derived cells can contribute to the myofibroblast population in fibrotic liver. 
This was discovered when a female patient that received a bone marrow 
transplant from a male donor (Y-chromosome) subsequently developed 
cirrhosis (66). The patient’s liver contained 12.4% of Y-chromosome positive 
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myofibroblasts, which indicated that these myofibroblasts were of bone 
marrow origin (66). Following this, a mouse model was used in which female 
mice underwent bone marrow transplantation from a male donor followed by 
treatment with carbon tetrachloride (CCl4) to induce liver fibrosis. This study 
demonstrated that 70% of myofibroblasts were of bone marrow origin (90). 
This outcome was also repeated in a bile duct ligation (BDL) mouse model of 
fibrosis (65). Transplantation of male MSC and female haematopoietic stem 
cells or vice versa into female mice confirmed that the myofibroblast 
population were of MSC and not haematopoietic stem cell origin (90). 
However it was not determined whether MSC immediately differentiate into 
myofibroblasts or whether they require transition through another cell type 
such as HSC (90). 
The characteristics of MSC mentioned above are ideal for cell therapy to treat 
fibrosis and cirrhosis. MSC could be transplanted into the fibrotic liver to avoid 
liver transplantation. However, some doubts about their therapeutic effects of 
MSC for liver fibrosis remain, as MSC can also differentiate into 
myofibroblasts. 
1.5 TNF Superfamily  
Cytokines and their receptors that are of potential interest for fibrogenesis, 
belong to the tumour necrosis factor (TNF) superfamily. One of the best-
known cytokines of this family is TNF-α, which is a central player in 
inflammation. TNF-α is an important regulator of the nuclear factor kappa light 
chain enhancer of activated B cells (NF-κB) pathway that is involved in 
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controlling expression of genes that influence inflammation, proliferation, 
differentiation and cell migration (91).  
 
MSC can migrate out of the bone marrow to sites of injury and inflammation, 
which can be enhanced by TNF-α and it has been demonstrated that TNF-α 
enhances the proliferative potential of MSC (92). In addition, TNF-α is 
involved in the immunosuppressive ability of MSC in vivo and in vitro (80) and 
can increase adhesion of MSC to hepatic endothelium (unpublished data from 
V. Aldridge). Furthermore, Kupffer cells, the resident liver macrophages, 
secret TNF-α during fibrosis, which has been shown to have an anti-apoptotic 
effect on activated HSC (93). These studies show that the influence of TNF-α 
plays a critical part in modulating fibrosis and influence the physiological 
properties of mesenchymal progenitor cells.  
 
1.5.1 TWEAK and its Receptor Fn14 
The TNF and TNF receptor (TNFR) superfamily has several members and 
part of this superfamily is the recently identified cytokine, TNF-like weak 
inducer of apoptosis (TWEAK) and its receptor FGF-inducible molecule-14 
(Fn14). TWEAK is synthesised as type II-transmembrane protein that can be 
proteolytically cleaved to function primarily as a soluble cytokine (94). It is 
highly expressed by immunocytes and has been detected in tissues with 
acute injury and inflammation (95,96).  
TWEAK’s receptor, Fn14 is the smallest receptor of the TNFR superfamily. It 
is a 14-kDa type I transmembrane receptor with only one cysteine-rich domain 
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at its extracellular ligand-binding region (97). In healthy tissue, Fn14 is 
expressed in low levels whereas high expression levels can be detected in 
tissues with inflammation. When Fn14 is up-regulated, it associates with TNF 
receptor associated factors (TRAFs) via its cytoplasmic domain and activates 
NF-κB (98). Compared to TNF-α, TWEAK induces a prolonged NF-κB 
activation (99). This indicates TWEAK’s potent ability to contribute to 
inflammatory diseases. In addition, TWEAK-dependent Fn14 signalling has 
been shown to regulate several cellular processes including proliferation, 
differentiation, migration, angiogenesis, apoptosis and proinflammatory 
responses similar to its sibling TNF-α (100).    
1.5.2 TWEAK-dependent Fn14 Signalling in Disease 
Several studies in recent years have indicated that TWEAK-dependent Fn14 
signalling has a role in the pathogenesis of inflammatory diseases. Those 
studies showed that overexpression of TWEAK in various tissues of mice can 
lead to profound dilated cardiomyopathy (101) skeletal muscle wasting (102) 
and breakdown of the blood-brain barrier (103). In addition, administration of 
TWEAK to normal mice led to features of inflammatory kidney disease (104). 
In contrast, other studies using TWEAK neutralising monoclonal antibodies 
(mAb) or Fn14 deficiency have shown to be beneficial during injury. Mouse 
models of human systemic lupus erythematosus (SLE) nephritis for example 
had decreased disease severity when they did not express Fn14 or were 
treated with anti-TWEAK mAb (105).  
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Overall, these observations indicate that overactive TWEAK-dependent Fn14 
signalling can be detrimental and that deficiency of TWEAK-dependent Fn14 
signalling can be beneficial to pathological outcomes. 
 
Although the activity of TWEAK is often associated with detrimental effects in 
inflammatory diseases, it has been reported that TWEAK’s activity can also 
be beneficial. Two studies showed that TWEAK is a mitogen for liver 
progenitor cells, which indicates that TWEAK can be involved in liver 
regeneration (106,107). Fn14 is normally not detectable in a healthy liver, 
which mainly contains hepatocytes but becomes up-regulated in human 
hepatocellular carcinoma tissue (108). Also, Fn14 expression becomes up-
regulated in hepatocytes of mice within 4 hours after a partial hepatectomy 
and during hepatocarcinogenesis compared to normal mouse livers (108). 
This implies that TWEAK and Fn14 have an important role during proliferation 
of hepatic epithelial cells and therefore liver regeneration. Furthermore, it has 
been suggested that Fn14 is not the only receptor for TWEAK (109). However, 
with an Fn14-null mouse model Jakubowski et al. demonstrated that 
TWEAK’s mitogenic effect on liver progenitor cells is Fn14 dependent (107). 
In addition, it has been demonstrated that MPC also express Fn14 (110). 
 
TWEAK can bind to several other progenitor cells, including MSC and muscle 
myoblasts (110). Muscle myoblasts exhibited increased proliferation when 
stimulated with TWEAK and decreased proliferation when treated with an anti-
Fn14 blocking antibody in vitro. Also, Fn14-null mice showed delayed muscle 
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regeneration and inflammatory responses (110). These results identify 
TWEAK as new modulator of regenerative myogenesis. Adipose tissue-
derived mesenchymal stem cells (AMNC) also express TWEAK and Fn14 and 
their interaction affects differentiation into adipocytes (111). Research shows 
that Fn14 expression decreases when ADMC or MSC undergo adipogenesis. 
In accordance to that TWEAK has been demonstrated to inhibit adipogenesis 
and is present in immature adipose tissue but not in mature adipose tissue 
(111). Moreover, MSC were affected by TWEAK stimulation, showing an up-
regulation of NF-κB and expression of pro-survival, pro-proliferative and cell 
adhesion genes (110). 
 
TWEAK-dependent Fn14 signalling is involved in inflammation and in 
progenitor proliferation and differentiation. Understanding how Fn14 signalling 
influences MPC proliferation and differentiation would be a great success in 
the progress of cell therapy for fibrosis.  
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2. OBJECTIVES 
Despite advances in understanding the pathology of fibrosis, there is limited 
therapy available. Cell therapy with MPC could be a promising approach to 
find treatment for hepatic fibrosis and cirrhosis. MSC that have been 
demonstrated to modulate the immune system and potentially contribute to 
liver repair are prospective new therapeutic agents to target liver fibrosis. 
However, MSC might also contribute to the pathogenesis of fibrosis by 
differentiating into myofibroblasts. Therefore it is crucial to further investigate 
the basic biology of MSC and the behaviour of MSC when they are exposed 
to factors from microenvironment of a fibrotic liver. Furthermore finding a way 
to prevent activation or induce apoptosis of HSC would be another promising 
way to treat liver fibrosis. Recent studies have demonstrated the involvement 
of TWEAK-dependent Fn14 signalling in progenitor proliferation and 
differentiation. To investigate whether TWEAK-dependent Fn14 signalling 
affects MSC, we will carry out experiments to test Fn14 and TWEAK 
expression on MSC, the effect of adipogenesis on Fn14 expression and the 
influence of TWEAK on adipogenesis and MSC survival. In addition, we will 
investigate Fn14 expression on HSC. 
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3. MATERIALS AND METHODS 
 
Unless otherwise stated human MSC and appropriate media were obtained 
from LONZA (Wockingham, UK) and human HSC and appropriate media 
were obtained from TCS Cellworks (Buckingham, UK).   
3.1 Setting up Human MPC Cultures 
For long-term storage, MPC were kept in liquid nitrogen (-150ºC). To set up 
MPC cultures, cryovials were removed from storage and disinfected with 70% 
ethanol before opening. In a sterile environment cells where thawed by adding 
room temperature, sterile phosphate buffer saline (PBS). Thawed cell were 
transferred to 25ml tube containing 25ml sterile PBS and centrifuged for 5 
minutes at 726g to pellet cells. The pellet was resuspended in the appropriate 
medium for each cell type (Table 1) by gently pipetting up and down. For MSC, 
cell suspension was transferred to a 175cm2 culture flask (BD Falcon) 
containing 25ml supplemented MSCBM (Table 1). HSC suspension was 
transferred to a 75cm2 culture flask (Corning) pre-coated with poly-L-lysine 
(0.1 mg/ml in TC grade distilled water; Sigma, Poole, UK) containing 10ml 
HSC medium (ScienCell, Buckingham, UK) (Table 1). Flasks were rocked to 
distribute cells over flask surface and incubated at 37ºC 5%CO2 in a 
humidified environment for at least 12 hours.   
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Type of Cells Medium Volume (ml) 
MSC Mesenchymal Stem Cell Basal 
Medium (MSCBM) 
- Mesenchymal Growth 
Supplement (MCGS) 
- L-Glutamine 
- GA-1000 
 
440 
 
 
50 
10 
0.5 
HSC SteCM Stellate Cell Medium - 
Table 1.  Media for MPC 
 
3.2 Maintenance of Human MPC  
3.2.1 Passaging MPC 
In a sterile environment, 10 or 15ml medium (depending on whether it was a 
75 or 175cm2 culture flask) was removed and transferred into a 25ml tube. 
The cells were rinsed with sterile PBS, which was then discarded and 5 or 10 
ml TrypLE (Gibco) added. Flaks were gently tapped to detach cells from the 
plastic and viewed under a microscope to ensure detachment. The medium 
retained at the beginning was added to the flask to inactivate TrypLE. The cell 
solution was then transferred to a 25ml tube and centrifuged for 5 minutes at 
726g to pellet the cells. The cell pellet was resuspended in the appropriate 
medium (Table 1) by gently pipetting up and down and transferred into new 
flasks containing pre-warmed MSCBM (for MSC) or HSC medium. Flasks 
were rocked to distribute cells over flask surface and incubated at 37ºC 
5%CO2 in a humidified environment. Medium was changed every 2-3 days 
completely. Cells were passaged when reaching around 85% confluency.    
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3.2.2 Cryopreservation for MPC 
Cells were detached from flask as described in section 3.2.1. After 
centrifugation supernatant was removed and cells were resuspended in 3ml of 
cryopreservation medium (5%DMSO in foetal calf serum (FCS)). 500,000 to 
2,000,000 cells per ml were added per cryovial and the vials were stored in a 
“Mr Frosty” containing 250ml propan-2-ol at -80ºC for at least 24 hours. For 
long-term storage, the cryovials were stored at -150ºC in liquid nitrogen.   
3.3 Flow Cytometry  
3.3.1 Cell Surface Flow Cytometry 
Depending on the experiment, cells were either treated 24 hours in advance 
to the experiment or left untreated. MSC were treated with TNF-α (1:1000, 
10µg/ml) (Peprotech, London, UK) and HSC were treated with human TGF-β 
(1:1000, 10µg/ml) (Peprotech, London UK). Cells were detached from the 
flask as described in in section 3.2.1. After centrifugation, the supernatant was 
removed and cells were resuspended in FACS buffer (10% FCS in sterile 
PBS). 100µl of cell suspension was added to each FACS tube. Primary 
antibodies for Fn14/TWEAK staining or conjugated-antibodies for MSC 
markers (Table 2) were added to individual FACS tubes and incubated at 4ºC 
for 30 minutes with agitation in the dark. After 30 minutes, cells were washed 
twice with FACS buffer and centrifuged for 5 minutes at 726g. FACS tubes 
with antibodies against MSC marker were immediately analysed on a flow 
cytometer. During Fn14/TWEAK staining, the supernatant was removed and 
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100µl of secondary antibody Alexa Fluor 488 (1:250, goat anti-mouse IgG, 
Invitrogen, Paisley, UK) diluted in FACS buffer was added to each FACS tube. 
Cells were then incubated at 4ºC for 30 minutes with agitation in the dark. 
After 30 minutes, cells were washed twice with FACS buffer and centrifuged 
for 5 minutes at 726g. The supernatant was removed and cells were 
resuspended in 500µl FACS buffer and analysed immediately using a CyAn 
flow cytometry machine (Dako) and Summit software Version 3. Experiments 
were repeated with multiple MSC donors. 
 Primary 
Anitbody 
Dilution Stock 
concentration 
Supplier 
Fn14 
expression 
Control - - - 
 IgG1* 1:50 300µg/ml Gift from Biogen 
Idec Inc. 
 Fn14* 1:50 370µg/ml Gift from Biogen 
Idec Inc. 
TWEAK 
expression 
Control - - - 
 IgG2a* 1:50 398.5µg/ml Gift from Biogen 
Idec Inc. 
 TWEAK* 1:50 324µg/ml Gift from Biogen 
Idec Inc. 
MSC markers Control - - - 
 CD73* 1:10 - Miltenyi Biotec, 
Surrey 
 CD90* 1:10 - Miltenyi Biotec, 
Surrey 
 CD105* 1:10 - Miltenyi Biotec, 
Surrey 
 Test-Mix* 1:10 - Miltenyi Biotec, 
Surrey 
 IgG-Mix* 1:10 - Miltenyi Biotec, 
Surrey 
* Mouse anti-human  
Table 2.  Primary antibodies for Fn14 and TWEAK surface expression and antibodies from 
MSC Phenotyping Kit (Miltenyi Biotec, Surrey, UK; #130-095-198) 
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3.3.2 Intracellular Flow Cytometry for TWEAK 
For intracellular staining, cells were removed from flask as described in 
section 3.2.1 and resuspended in 2% paraformaldehyde (PFA) in PBS. Cells 
were then incubated for 20 minutes at 4ºC. After 20 minutes, cells were 
washed with permeabilisation buffer (1X BD Perm/Wash buffer in hH2O, BD 
Biosciences, Swindon, UK) for 15 minutes and centrifuged for 5 minutes at 
726g twice in 500µl permeabilisation buffer. Cell pellet was resuspended in 
300µl permeabilisation buffer and 100µl of cell suspension was added to each 
FACS tube. Cells were then stained according to the protocol in section 3.3.1 
starting from the step where primary antibodies (Table 2, TWEAK expression) 
are added. Instead of FACS buffer, permeabilisation buffer was used 
throughout the protocol except at the final step when 500µl FACS buffer was 
added.  
3.4 Adipogenic Differentiation of MSC 
MSC were differentiated into adipocytes using hMSC adipogenic 
differentiation BulletKit according to the manufacturers protocol (LONZA, 
Wockingham, UK, PT-3004). Briefly, 2x105 cells were plated per well in a 6-
well plate and incubated at 37ºC 5%CO2 in a humidified environment until 
reaching 100% confluence. Once confluent, cells were treated with induction 
medium for 3 days and the maintenance medium for 2-3 days (Table 3). 
Controls were treated at the same schedule with either maintenance medium 
only or MSC medium only. This was repeated for 3 cycles and after 
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completion, cells were cultured for another 7 days in maintenance medium. 
Controls that had been treated with MSC medium only were continued to be 
treated with the same medium.  
For a separate experiment, TWEAK protein (1:1000, 10µg/ml) (Gift from 
Biogen Idec Inc., Cambridge, USA) was added to the MSC culture at the 
beginning of each cycle.  
 
At the end of each cycle, flow cytometry analyses for Fn14 expression and Oil 
Red O staining were carried out. In addition, MSC were observed through a 
microscope at twenty times magnification and photos were taken with a 
Canon EOS 40D.   
 
 
 Content Volume (ml) 
Maintenance Medium  Adipogenic Maintenance Medium 
- h-Insulin  
- L-Glutamine 
- MCGS 
- GA-1000 
170 
2 
4 
20 
0.2 
Induction Medium Adipogenic Induction Medium 
- h-Insulin 
- L-Glutamine 
- MCGS 
- Dexamethasone 
- Indomethacin 
- IBMX 
- GA-1000 
170 
2 
4 
20 
1 
0.4 
0.2 
0.2 
Table 3.  Media used for adipogenic differentiation of MSC 
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3.4.1 Oil Red O Staining 
Oil Red O (Sigma-Aldrich) was prepared by adding 15ml of Oil Red O stock 
solution (0.25g Oil Red O in 50ml 100% Isopropanol) to 10ml of distilled (d) 
H2O and incubated for 10 minutes at room temperature. The solution was 
then filtered two times through a filter paper (Whatman).  
At the end of the differentiation protocol the cells were fixed in formal saline 
solution for 10 minutes and then washed twice with PBS. PBS was aspirated 
and 60% Isopropanol in dH2O was added to wells for 5 minutes. The 
Isopropanol was then aspirated and cells were incubated at room temperature 
for 1 hour in freshly prepared Oil Red O. Oil Red O was removed and 60% 
Isopropanol was added and incubated for 5 minutes. The cells were then 
washed twice with dH2O. Images were taken with a Canon EOS 40D.  
 
For quantification, Oil Red O was solubilised by adding 500µl of 100% 
Isopropanol to each well and then incubated for 10 minutes on a plate shaker. 
500µl of each well were evenly distributed between 5 wells of a 96-well plate 
and the released stain was quantified using a Synergy HT plate reader (BIO-
TEK). Readings were taken at 520nm. 100% Isopropanol only was used to 
determine background staining.  
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3.5 4-Colour Apoptosis, Necrosis, ROS 
production, Autophagy Assay 
 
The 4-colour assay was used to determine reactive oxygen species (ROS) 
production, autophagy, apoptosis and necrosis. To determine ROS production, 
the non-fluorescent substrate 2’,7’-dichlorofluorescin-diacetate (H2DCF; 
Merck, Nottingham, UK) was used. H2DCF is cell permeable and once inside 
the cell it becomes trapped as a result of hydrolysis by intracellular esterases 
to 2’,7’-dichlorofluorescin (DCF) (112). DCF then reacts with ROS leading to 
production of green fluorescence. Autophagy was determined with the 
autofluorescent compound monodansylcadaverine (MDC) (Fluka, Sigma-
Aldrich) that labels autophagic vacuoles (113). Annexin-V (Molecular Probes, 
Paisley, UK) was used to detect apoptosis. When cells undergo apoptosis, 
phosphatidyl serine is translocated to the cell surface where Annexin-V will 
bind it with high affinity (114). 7-Amino-Actinomycin D (7-AAD, Molecular 
Probes, Paisley, UK) is a fluorescent compound that determines necrosis. 7-
AAD can only enter a cell when the plasma membrane is disrupted but once 
inside a cell it binds with high affinity to DNA (115).   
 
MSC were plated into 6-well plates and when 85% confluent MSC were 
treated with TWEAK (1:1000, 10µg/ml), TNF-α (1:1000, 10µg/ml) or left 
untreated. After 12 or 24 hours the medium was aspirated and 2ml HBSS -
Ca2+, -Mg2+ (Gibco) was added. 6µl of DCF and 1µl of MDC were added to 
each well and incubated at 37ºC for 30 minutes in the dark with agitation. The 
  
  Materials and Methods      
76 
wells were then treated with 2ml TrypLE at 37ºC for 5 minutes in the dark. To 
ensure all cells were detached TrypLE was gently pipetted up and down. 
Then 2ml of FCS was added to inactivate the TrypLE and the cell solution 
was transferred to a 15ml tube. The cells were washed in PBS and 
centrifuged at 726g for 5 minutes twice. PBS was removed and 100µl PBS 
was added and transferred into a FACS tube. 5µl Annexin-V and 2µl 7-AAD 
was added to each FACS tube and incubated for 15 minutes on ice. Next, 
400µl PBS were added and the samples were immediately analysed by flow 
cytometry. 
In order to compensate, one well was treated with each fluorescent substrate 
alone to avoid crossover of fluorophores. Approximately 10,000-gated cells 
were counted for each experiment.  
3.6 Immunofluorescence 
Cells were plated on sterile glass coverslips in 24-well plates. MSC were 
treated with TNF-α (1:1000, 10µg/ml) and HSC were treated with TGF-β 
(1:1000, 10µg/ml; both Peprotech, London UK). After 24 hours, the medium 
was aspirated and cells were fixed for 15 minutes in 4% PFA in PBS. After 
rinsing wells with PBS, 4 drops of Image-iT signal enhancer (Invitrogen) were 
applied and incubated for 30 minutes. Wells were rinsed with PBS and 
blocked with 10% goat serum (Vector Laboratories, Petersborough, UK) in 
PBS/0.3% TritonX (Sigma-Aldrich) for 10 minutes. Each well was then treated 
with primary antibodies (Table 2, Fn14 expression) at a 1:50 dilution in 10% 
goat serum in PBS/0.3% TritonX for 1 hour. After 1 hour, wells were washed 3 
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times for 10 minutes with PBS. The secondary antibody, Alexa Fluor 488 
(goat anti-human IgG) was applied in a 1:500 dilution in 10% goat serum in 
PBS/0.3% TritonX and incubated for 1 hour in the dark. Wells were washed 3 
times for 10 minutes with PBS, incubated with DAPI (Invitrogen) at a 1:5000 
dilution in PBS for approximately one minute and then rinsed with PBS/0.1% 
TritonX. Fluoromount mounting medium (Dako) was used to mount coverslips 
and left to dry. Slides were then viewed with an epi-fluorescent microscope 
and Axiovision software was used to capture images (both Carl Zeiss 
MicroImaging, LLC, Thornwood, NY). 
3.7 Statistical Analysis 
 
If not stated otherwise an N value of 3 was obtained. The Student T Test was 
carried out and a P value of < 0.05 was considered as significant.   
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4. RESULTS 
4.1 Characteristics of MSC 
MSC have a fibroblast like appearance (Figure 3A) and can differentiate into 
various cell types including chondrocytes, osteocytes and adipocytes 
(previously performed by V. Aldridge). Flow cytometry analysis showed that 
MSC population was heterogeneous in size and granularity as shown with the 
forward and side scatter dot blot (Figure 3B). As expected the MSC marker kit 
showed that MSC were positive for CD73, CD90 and CD105 and negative for 
CD14, CD20, CD34 and CD45 (Figure 3C).  
 
 
Figure 3. Morphology and expression of surface molecules Morphology of MSC, 
Scale bar 100µm (A) Forward versus side scatter with at least 10,000 gated events and 
isotype control (B) CD73+, CD90+ and 105+ cells and CD14-, CD20-, CD34- and CD45-cells 
(fluorescent dye PerCP) (C) 
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4.2 Expression of Fn14 on MSC 
Flow cytometry was used to determine Fn14 expression on MSC. The pulse 
width was used to distinguish single cells from cell clumps or aggregates 
(Figure 4A). MSC were treated with TNF-α for 24 hours or left unstimulated. 
On average 93% of MSC expressed Fn14 and that slightly increased to an 
average of 98% with TNF-α stimulation (Figure 4B-C). The median 
fluorescent intensity (MFI) describes the number of receptors present per cell. 
On average a greater MFI was detected on TNF-α stimulated cells (71) 
versus unstimulated cells (50) but the increase was not statistically significant 
(p > 0.05) (Figure 4C). Fn14 expression was also detected with 
immunocytochemistry on unstimulated and TNF-α stimulated MSC (Figure 
4D).  The fluorescent staining appears to be stronger in TNF-α treated cells 
than unstimulated cells, which correlates with the MFI from flow cytometry 
(Figure 4C-D).  
Overall, the percentage of unstimulated and TNF-α stimulated cells 
expressing Fn14 is very similar. However, it seems that cells that have been 
stimulated with TNF-α have slightly more Fn14 receptors on the cell surface 
than untreated MSC.  
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Fig 4. Fn14 expression on MSC . Forward versus side scatter with at least 10,000 gated 
events and pulse width (A) Flow cytometric analysis of Fn14 expression on unstimulated and 
TNF-α stimulated MSC (B) Percent of Fn14 positive cells and MFI of unstimulated and TNF-α 
stimulated MSC, each symbol represents an individual donor (C) Unstimulated and TNF-α 
stimulated MSC positive for Fn14 expression counterstained with DAPI. Scale bar, 200µm. 
Scale bar merged X40 50µm (D) 
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4.3 Expression of TWEAK on MSC 
MSC were examined for TWEAK expression with flow cytometry (Figure 5). 
No TWEAK expression was detected on the cell surface of either 
unstimulated or TNF-α stimulated MSC (Figure 5A). Furthermore, no TWEAK 
expression was detected intracellularly in unstimulated MSC (Figure 5B).   
 
 
Fig 5. TWEAK expression on MSC . Forward versus side scatter with at least 10,000 
gated events (A+B) Flow cytometric analysis of TWEAK expression on the cell surface of 
unstimulated and TNF-α stimulated MSC (A) Intracellular TWEAK expression of unstimulated 
and TNF-α stimulated MSC (B) 
4.4 Fn14 Expression during Adipogenesis 
To investigate whether differentiation of MSC affects Fn14 expression, MSC 
were differentiated over 3 weeks into adipocytes. Differentiation into 
adipocytes was confirmed by formation of cytoplasmic lipid vacuoles. Oil Red 
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O was used to stain lipid vacuoles red (Figure 6). Not all cells in the culture 
differentiated into adipocytes. Cells treated with MSC medium or Maintenance 
medium as a control did not change morphology and did not stain red with Oil 
Red O (Figure 6).   
 
Fig 6. MSC differentiation into adipocytes.  Induction and maintenance medium were 
used to induce adipogenesis in MSC. MSC medium and maintenance medium only were 
used as a control. Oil Red O staining confirmed cytoplasmic lipid vacuoles that form during 
adipogenesis.  Scale bar 30µm 
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Flow cytometry was used to analyse the expression of Fn14 on MSC during 
the course of differentiation. MSC populations treated with MSC or 
maintenance medium remained heterogeneous in size and granularity as 
shown with the forward and side scatter dot blot (Figure 7A, insert). 
Differentiation of MSC into adipocytes resulted in greater variability in forward 
and side scatter properties (Figure 7A, insert).  
After the first cycle (5 days in culture) the average Fn14 expression in MSC 
medium is 95%, in maintenance medium 91% and in adipogenesis medium 
89%. After the second cycle (9 days in culture) the average Fn14 expression 
in MSC medium is 86%, in maintenance medium 53% and in adipogenesis 
medium 84%. After the third cycle (14 days in culture) the average Fn14 
expression in MSC medium is 48%, in maintenance medium 20% and in 
adipogenesis medium 57%. After the forth and final cycle (21 days in culture) 
the average Fn14 expression in MSC medium is 22%, in maintenance 
medium 7% and in adipogenesis medium 48%. Average Fn14 expression 
decreases from the first to the final cycle by 41% in the adipogenic culture, 
74% on cells treated with MSC medium and 84% on cells treated with 
maintenance medium (Figure 7).  
 
The average MFI after the first cycle is 42 in MSC medium, 40 in maintenance 
medium and 43 in adipogenesis culture. After the second cycle the average 
MFI is 22 in MSC medium, 39 in maintenance medium and 43 in 
adipogenesis culture. After the third cycle the average MFI is 21 in MSC 
medium, 36 in maintenance medium and 21 in adipogenesis culture. After the 
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final cycle the average MFI is 29 in MSC medium, 48 in maintenance medium 
and 23 in adipogenesis culture.  The MFI drops significantly (p< 0.01) from 
cycle 1 to cycle 3 when cells were treated with MSC medium or adipogenic 
medium but drops minimally when cells were treated with maintenance 
medium. Also the MFI rises in the final cycle in cultures with maintenance or 
adipogenic medium (Figure 7B). Overall, Fn14 expression decreased during 
adipogenesis but it cannot be said that this was as a result of adipogenic 
differentiation as both control groups also lost Fn14 expression. 
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Fig 7. Fn14 expression during adipogenesis.  Adipogenesis was induced by three 
cycles of induction and maintenance medium and then 7 more days in maintenance medium. 
MSC and maintenance media were used as a control. Flow cytometric analysis for F14 
expression of MSC cultures in control media and during adipogenesis (A). Mean percentage 
of Fn14 positive cells and mean MFI during 4 cycles of adipogenesis (B) Each experiment 
was carried out in triplicate. 
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4.5 Effect of TWEAK on Adipogenesis 
TWEAK has previously been demonstrated to interfere with adipogenic 
differentiation of adipose tissue derived mesenchymal cells (ADMC) (111). 
Therefore we decided to study the effects of TWEAK on MSC during 
adipogenesis. No morphological changes of cells were detected during 
adipogenesis compared to cells that were not stimulated with TWEAK (Figure 
8A). An accumulation of cytoplasmic lipid vacuoles was detected and 
confirmed with Oil Red O staining in untreated and treated cultures (Figure 
8A). Performing fat quantification by measuring the amount of Oil Red O stain 
in culture confirmed that TWEAK did not affect differentiation potential of MSC 
(p > 0.05) (Figure 8B). However, when MSC were treated with maintenance 
medium plus TWEAK the culture seemed to be more confluent than treatment 
with maintenance medium alone. This could indicate that TWEAK has an 
effect on proliferation on MSC but more experiments need to be carried out in 
order to confirm this hypothesis (Figure 8A).   
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Fig 8. MSC differentiation into adipocytes in the presence of TWEAK.  Induction 
and maintenance medium were used to induce adipogenesis in MSC with or without TWEAK. 
Maintenance medium were used as a control. Oil Red O staining confirmed cytoplasmic lipid 
vacuoles.  Scale bar 30µm (A) Fat accumulation was measured with a plate reader at 520nm 
Values are means ± SEM. (B)  
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4.6 Effect of TWEAK on Apoptosis, Necrosis, 
ROS Production and Autophagy 
To further investigate how TWEAK might influence MSC behaviour, a four-
colour flow cytometry assay was carried out to detect apoptosis, necrosis, 
autophagy and ROS production. MSC were treated with TWEAK, TNF-α or 
left unstimulated for either 12 or 24 hours. After 12 or 24 hours of stimulation, 
TWEAK or TNF-α did not change levels of apoptosis significantly compared to 
the untreated control (Figure 9B). Nevertheless a slight increase of apoptosis 
was detected during the second experiment when cells were treated with 
TWEAK compared to untreated control (Figure 9B). TNF-α stimulation for 12 
hours increased levels of necrosis slightly but not for 24 hours compared to 
the untreated control. Stimulation of MSC with TWEAK for 12 hours did not 
seem to have an effect on necrosis but slightly increased levels of necrosis in 
the second 24 hours experiment. (Figure 9C). Although the changes in 
histograms have been minor it appears that TWEAK induces cell death 
considering the low number of cells detected after the second 24 hours 
experiment.  
ROS production was enhanced after 12 hours and the first 24 hours 
experiment but not the second 24 hours experiment with TNF-α stimulation 
(Figure 9D). TWEAK stimulation did not change levels of ROS production 
after 12 hours or the second 24 hours experiment but increased ROS 
production slightly after the first 24 hours experiment (Figure 9D).  
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Surprisingly, treatment with TWEAK led to a substantial decrease of 
autophagy after the second 24 hours experiment compared to unstimulated 
control and TNF-α (Figure 9E) but could not be repeated after 12 or 24 hours 
(Figure 9E). TNF-α stimulation slightly enhanced levels of autophagy after 12 
hours but not after 24 hours compared to the untreated control (Figure 9E).  
 
Overall, TNF-α stimulation did not seem to affect apoptosis, necrosis, ROS 
production or autophagy in MSC. In addition, TWEAK stimulation did not have 
a great impact on levels of apoptosis, necrosis and ROS production except on 
levels of autophagy and cell death in one experiment after 24-hour stimulation 
(Figure 9, 2: 24 hours).  
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Fig 9. Flow cytometric analysis of apoptosis, necrosis, ROS production and 
autophagy in MSC.  MSC were stimulated for 12 or 24 hours with TWEAK or TNF-α. 
Forward versus side scatter with at least 10,000 gated events after 12, first 24 or second 24 
hours (A) Flow cytometry analysis was carried out for apoptosis (B) necrosis (C) ROS 
production (D) and autophagy (E). Presented data is for individual experiments.  
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4.7 Fn14 Expression on HSC 
Since there is no published data regarding Fn14 expression on HSC, Fn14 
expression was investigated with flow cytometry and immunocytochemistry on 
unstimulated and TGF-β stimulated HSC. HSC have a star-like morphology 
(Figure 10A) but when they are treated with TGF-β they become activated 
and form clusters (116) (Figure 10B). Flow cytometry analysis showed that 
83% of unstimulated HSC and 89% of TGF-β stimulated HSC expressed 
Fn14 (Figure 10C).  
The MFI of Fn14 in unstimulated HSC is 38 but it significantly increases to 49 
(p= < 0.05) when HSC were stimulated with TGF-β. Fn14 expression was 
confirmed with immunocytochemistry on unstimulated and TGF- β stimulated 
HSC (Figure 10D).  
Overall, there has been in an increase in MFI and Fn14 expressing HSC 
when they were stimulated with TGF-β.  
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Fig 10. Fn14 expression on HSC Morphology of HSC (A) Morphology of TGF-β 
stimulated HSC compared to unstimulated HSC (B) Flow cytometric analysis of Fn14 
expression on unstimulated and TGF-β stimulated HSC (C) Unstimulated and TGF-β 
stimulated HSC positive for Fn14 expression counterstained with DAPI. Scale bar, 200µm. 
Scale bar merged X40 50µm (D)  
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5. DISCUSSION 
 
Currently the only effective treatment for cirrhosis is liver transplantation. 
However, the lack of available organs and the fact that transplant patients have 
to take lifelong toxic immunosuppressive medications leads to a need to 
discover novel treatments. Cellular therapies using stem cells such as MSC 
provide a promising approach. MSC are easy to isolate and cultivate, can 
modulate the immune system and can differentiate into hepatocytes. Another 
possible therapeutic approach would be to reduce the number of ECM 
producing myofibroblasts within the liver. HSC are the main cell type to give rise 
to myofibroblast when they become activated during liver injury. Therefore, 
inhibiting HSC activation or causing apoptosis provide another possible 
approach to reduce liver fibrosis.  
 
It has been demonstrated that TWEAK-dependent Fn14 signalling is involved in 
stimulating properties of MSC including activation of pro-survival, pro-
proliferative and cell adhesion genes (110). Fn14 expression is very low on 
hepatocytes in normal livers but becomes highly up-regulated on hepatocytes 
during liver regeneration (108). In addition, TWEAK is highly expressed by 
immunocytes and has been detected in tissues with acute injury and 
inflammation (95,96). Being able to understand how TWEAK-dependent Fn14 
signalling affects MSC during transplantation into a fibrotic liver would be a 
major advantage for cell therapy. It has been demonstrated that MSC can 
differentiate into myofibroblasts (90). Therefore it would be beneficial to look at
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 the effect of TWEAK on MSC differentiation in order to advance to safe cell 
therapy. Also, to understand how TWEAK-dependent Fn14 signalling might 
affect HSC activation during fibrosis may provide us with another avenue for 
therapeutic intervention.  
5.1 Expression of TWEAK and Fn14 on MSC 
MSC used for this project were heterogeneous in size and displayed a fibroblast 
like morphology. They expressed the surface markers CD73, CD90 and CD105 
and were negative for the haematopoietic markers CD34 and CD45, the B cell 
marker CD20 and the monocyte/macrophage marker CD14. One study has 
demonstrated that MSC express Fn14 (110). Carrying out flow cytometry on 
unstimulated MSC confirmed these findings.  
As mentioned above, TWEAK, TNF-α and their receptors are part of the same 
superfamily. MSC respond to TNF-α stimulation in a number of ways such as 
enhanced cell migration, proliferation (92), adhesion (unpublished data from V. 
Aldridge) and increased immunosuppressive abilities (80). In addition, bone 
marrow derived MSC have been demonstrated to respond to TNF-α stimulation 
causing NF-κB translocation (117). To investigate the effect of TNF-α on Fn14 
expression on MSC, we treated MSC with TNF-α for 24 hours. Treatment did 
not seem to affect the number of cells expressing Fn14 but it increased the MFI, 
which indicates that more Fn14 receptors were expressed per cell. This 
suggests that TNF-α makes MSC more susceptible to stimulation with TWEAK 
by inducing increased expression of Fn14. Immunocytochemistry confirmed that 
unstimulated and TNF-α stimulated MSC expressed Fn14.  
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It has not previously been reported whether MSC express TWEAK. Flow 
cytometry analysis showed that MSC did not express TWEAK on the cell 
surface or intracellular. This suggests that Fn14 signalling in MSC is not affected 
by autocrine action.  
5.2 Fn14 Expression during Adipogenesis 
As MSC highly express Fn14, we were interested to see whether MSC loose 
Fn14 expression during differentiation. Therefore, MSC were differentiated with 
an adipogenic differentiation kit and analysed after every cycle for Fn14 
expression. Flow cytometric analysis shows that Fn14 expression on MSC 
decreased steadily during adipogenesis. These results are in accordance with 
data published by Alexaki et al. who demonstrated that Fn14 expression 
decreases when adipose tissue derived mesenchymal cells (ADMC) or MSC 
undergo adipogenesis (111). They also showed that Fn14 translocates from the 
cell surface to inside the cell during adipogenic differentiation of ADMC (111). 
This could explain why the MFI drops after cycle 3 during adipogenesis of MSC. 
However, the expression of Fn14 is not completely lost and this may be 
explained by the fact that Fn14 is still expressed at low levels in adipose tissue 
(111). Furthermore, some undifferentiated cells remained within the adipogenic 
culture, therefore these cells may still express high levels of Fn14. A way of 
deciphering whether Fn14 expression is lost on our adipocytes would be to 
include an adipocyte-specific antibody in our flow cytometry analysis.  
Surprisingly, Fn14 expression also decreased in both control media. The cells 
remained MSC and kept on differentiating resulting in more cells per well. This 
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suggests that expression levels of Fn14 might be influenced by confluency. The 
maintenance medium decreased the number of MSC expressing Fn14 more 
than the MSC medium alone, suggesting it may contain factors not found in the 
MSC medium. Since we obtain the media commercially we are unable to 
determine whether there are any factors in the maintenance medium, which 
would affect Fn14 expression. 
5.3 Effect of TWEAK during Adipogenesis 
Corresponding to the decreasing levels of Fn14 during adipogenesis, TWEAK is 
present in immature adipose tissue but not in fully differentiated adipose tissue 
(110). Also, it has been demonstrated that TWEAK decreases adipogenic 
differentiation of ADMC (110). Treating MSC with TWEAK protein during 
adipogenesis did not seem to affect the differentiation potential of MSC. 
Surprisingly, treating MSC with maintenance medium and TWEAK appeared to 
enhance proliferation of MSC compared to treatment with maintenance medium 
alone. Low concentrations of TWEAK (2-10ng/ml) have been associated with 
increased proliferation of the Eph4 mammary epithelial cell line (118) whereas 
relatively high doses of TWEAK (100ng/ml) have been associated with cell 
death (118). For this experiment low doses of TWEAK (10ng/ml) seemed to 
induce proliferation, which would correlate with previous research. 
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5.4 Effect of TWEAK on Apoptosis, Necrosis, ROS 
Production and Autophagy on MSC 
MSC were treated for 12 or 24 hours with either TWEAK, TNF-α or left untreated. 
Treatment with TWEAK did not change levels of apoptosis in MSC significantly. 
However, a slight increase in apoptosis was detected in the second 24 hours 
experiment in which a different batch of TWEAK was used. Therefore it is 
unclear whether this is a real result or whether there are batch specific effects of 
TWEAK. More experiments would need to be carried out to address this. 
However, TWEAK has been reported to induce apoptosis in various cancer cell 
lines including Kym1 and OVCAR4 (119,120). The mechanisms by which TNF-α 
and TWEAK have been described to induce apoptosis include activation of 
transcription factor NF-κB (121), or TWEAK can induce apoptosis by secondary 
activation of TNF-α (119,120). Other described mechanisms for the action of 
TWEAK include TNF-α independent but caspase-dependent mechanisms (122). 
Fewer cells were present to carry out flow cytometry analysis in the second 24 
hours experiment compared to the other experiments, which indicates that cells 
died before the experiment was carried out. This could explain why levels of 
apoptosis did not increase significantly. Furthermore, it is also possible that 
TWEAK induced cell death in MSC via necrosis rather than apoptosis, as 
TWEAK has been reported to induce necrosis by reactive oxygen intermediates 
and cathepsin B-dependent pathways (122).  
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It has been demonstrated that apoptosis and necrosis can lead to an increase in 
ROS production resulting in oxidative stress (122). A slight increase of ROS 
production and necrosis was detected after 12 hours of stimulation with TNF-α. 
This is in accordance with other published data that demonstrates that TNF-α 
can induce necrosis, which seems to be mediated by production in ROS (123). 
In addition, TWEAK stimulation led to an increase in ROS production in the first 
24 hours experiment. It has been demonstrated that TWEAK can induce 
apoptosis through an increase in ROS production in 15d-PGJ2 sensitized cancer 
cells (124). This could suggest that cells with increased levels of ROS were 
about to undergo apoptosis.  
 
Autophagy is also involved in cell death and survival. During autophagy an 
autophagosome is formed that removes parts of the cytoplasm to either promote 
or prevent cell death (125). TNF-α stimulation caused a slight increase of 
autophagy after 12 hours but not after 24 hours. As necrosis and ROS 
production after 12 hours of TNF-α stimulation was also elevated an increase in 
autophagy could suggest that cells used autophagy to prevent cell death.  
The first batch of TWEAK did not change levels of autophagy after 12 or 24 
hours whereas the second batch of TWEAK decreased autophagy significantly 
compared to TNF-α and untreated control. It has been demonstrated that 
TWEAK can activate autophagy in cultured myotubes by increasing expression 
of autophagy-related molecules (126). This indicates that TWEAK can affect 
autophagy and it is possible that TWEAK might have an inhibitory effect on an 
autophagy related molecule in MSC, thereby inhibiting autophagy in this 
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specialised cell type. Alternatively, the remaining cells that have not already 
undergone cell death may have started to “commit” to death and therefore 
inactivated autophagy.  
5.5 Expression of Fn14 on HSC 
HSC play an important role during fibrogenesis and understanding how they are 
affected by their microenvironment would provide a crucial clue in the treatment 
of fibrosis. TWEAK has been detected in chronic liver injury (106) and TWEAK-
dependent Fn14 signalling can regulate several cellular processes including 
proliferation and differentiation (100). Therefore it might modulate HSC 
proliferation or influence differentiation of HSC into myofibroblasts. It would be a 
great progress to understand how TWEAK-dependent Fn14 signalling might 
affect HSC during fibrosis.  
We have demonstrated for the first time that a high number of unstimulated HSC 
express Fn14. To activate HSC, they were stimulated with TGF-β for 24 hours 
and subsequent flow cytometric analysis was carried out for Fn14 expression. It 
demonstrated that Fn14 expression was slightly increased compared to the 
untreated control. Furthermore, the MFI significantly increased when HSC were 
treated with TGF-β compared to untreated cells. This suggests that TGF-β 
stimulation makes HSC more susceptible to stimulation with TWEAK by 
increasing the levels of Fn14 expression. In addition, it was not determined 
whether TGF-β stimulation activated all HSC and the percentage of active HSC 
expressing Fn14. Examining the co-expression of Fn14 and α-SMA, which is a 
marker of activated HSC, could test this.  
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5.6 Future Experiments 
Fn14 expression decreased during adipogenesis but both control media also 
showed lower expression levels of Fn14. Therefore, it is not conclusive whether 
decreased levels of Fn14 were caused by MSC differentiation or by confluence. 
Using an adipocyte marker in addition to an Fn14 antibody could determine to 
what level adipocytes and the undifferentiated MSC express Fn14. In addition, 
Fn14 expression could be tested on MSC that have been plated at different 
densities starting from few cells to 100% confluence to test the affect of 
confluence on Fn14 expression. 
TWEAK did not affect adipogenic differentiation of MSC but seem to enhance 
proliferation. TWEAK has been demonstrated to enhance proliferation in liver 
progenitor cells (106). Therefore, it would be interesting to see whether TWEAK 
also enhances proliferation in MSC. To further investigate the effect of TWEAK 
on cell proliferation, MSC could be treated with TWEAK and proliferation could 
be quantified with a 5-bromo-2-deoxyuridine (BrdU) assay, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay or the Cellscreen 
system. 
The effect of TWEAK on apoptosis, necrosis, ROS production and autophagy in 
MSC is inconclusive as different batches of TWEAK show different results. More 
experiments need to be carried out with both batches of TWEAK. To determine 
whether TWEAK affects MSC survival, live cells could be quantified with trypan 
blue staining. Furthermore, terminal deoxynucleotidyl transferase-mediated 
biotinylated UTP nick end labeling (TUNEL) staining could be used to detect 
dead cells.  
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One donor has been used to show that HSC express Fn14. More donors are 
needed to confirm these results. TWEAK could be used to stimulate HSC with or 
without TGF-β to see the effect on HSC. In addition α-SMA staining needs to be 
carried out to assure that HSC have been activated. It would also be interesting 
to see whether TWEAK changes levels of apoptosis, necrosis, ROS production 
or autophagy in HSC.  
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